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ABSTRACT 
 WHO has reported that antibiotic resistance is the third major cause of human death all over 
the globe. Recent study, has focused on the development of new antibacterial resistance drugs. Herein, 
we tried to synthesis a series of polymers that can mimic the HDPs. HDPs can target the bacterial cell 
membrane and they have less chances to develop bacterial resistance. We synthesized the amphiphilic 
polycarbonates that are highly selective to Gram-positive bacteria, including multidrug resistant 
pathogens. The membrane disruption activity of these polymers was proved by fluorescence and TEM 
studies and the drug resistance study showed that the polymers don’t develop bacterial resistance. 
In order to further design the molecules that can target a broad spectrum of bacteria, we have designed 
a series of lipidated dendrimers that can target the Gram-positive and Gram-negative bacteria. These 
dendrimers mimic the HDPs and target the bacterial cell membrane. Dendrimers are reported to inhibit 
the formation of bacterial biofilm which makes them promising for their future development of 
antibiotic agents. 
Apart from the synthesis of polymers and dendrimers as antibacterial agents, we have designed 
a series of small molecular antibacterial agents that are based on the acylated reduced amide scaffold 
and small dimeric cyclic guanidine derivatives. These molecules display good potency against a panel 
of multidrug-resistant Gram-positive and Gram-negative bacterial strains. Meanwhile, they also 
effectively inhibit the biofilm formation. Mechanistic studies suggest that these compounds kill 
bacteria by compromising bacterial membranes, a mechanism analogous to that of host-defense 
peptides (HDPs). Lastly, we also demonstrate that these molecules have excellent in vivo activity 
against MRSA in a rat model. This class of compounds could lead to an appealing class of antibiotic 
agents combating drug-resistant bacterial strains.
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CHAPTER 1: INTRODUCTION 
1.1 Necessity of new Antimicrobial agents 
Bacterial infections pose a great threat to health of common people.1 The World Health 
Organization (WHO) has recognized that antimicrobial pathogens have developed resistance against 
most of the commercially available antibiotics that are currently present in the market.2 WHO have 
reported that there has been a significant increase in the infections caused by the drug resistant bacterial 
strains over a decade, especially from methicillin-resistant staphylococcus aureus (MRSA).3 About 
50-60% of the infections develop due to the lack in the sterility of the instruments used during 
surgeries.4 Infections caused due to sterility issues will lead to another post-surgical operation and in 
some extreme cases results in the removal of the infected part from the patient body.5 Therefore, there 
is a serious demand in the development of new antibacterial agents to combat the resistance developed 
by the bacteria against commercially available antibiotics.2 
1.2 General Characteristics of broad spectrum Antimicrobial drugs 
Most of the commercially available antimicrobial drugs are amphiphilic in nature. Although 
the mechanism of the antimicrobial peptides is in debate, most scientists believe that the peptides fold 
into their secondary alpha helix or beta sheet then interact with the bacterial cell membrane. Upon 
binding to the membrane peptides separate into distinct hydrophobic and hydrophilic chains.6 The 
hydrophilic groups of the peptide bind to the negatively charged bacterial cell surface by electrostatic 
attraction. The peptides show selectivity in binding to bacterial cells over human cells, as the bacterial 
surface is more abundantly negatively charged over the human cells which is almost considered to be 
neutral charged.7 The hydrophobicity of the drug helps in binding to the phospholipid bilayer of the 
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bacteria and helps in easy penetration of the drug. This amphiphilic nature of the drug helps in 
disrupting the bacterial cell membrane by altering the trans membrane potential which causes leakage 
of the cytoplasmic contents and ultimately leading to death.8 Although most of the currently 
synthesized antimicrobial peptides are believed to show their mechanism of action by membrane 
disruption, there are still peptides available that show their action by altering the cellular pathways of 
the bacteria and inhibiting the DNA/RNA synthesis, folic acid synthesis etc.6 
1.3 Differentiation between mammalian and bacterial cells 
Bacterial cells lack cholesterol in their membrane, whereas the mammalian cells have 25% 
cholesterol in their membranes which acts as a stabilizing factor for the cell.9 So due to lack of stability, 
disruption of the membrane becomes quite easier. Eukaryotic cells mainly contain phospholipids such 
as phosphatidylcholine, phosphatidylethanolamine and sphingomyelin. These cells carry a net neutral 
charge, whereas the negative charge is located in the inner leaflet of the membrane. Bacterial cells, 
both gram positive and gram negative have a net negative charge on the membrane due to the presence 
of phospholipids such as phosphatidyl glycine, phosphatidylserine and cardiolipin on the outer leaflet 
membrane making it more susceptible to the drugs over the mammalian cells.5 In addition to this, gram 
positive bacteria has a thick peptidoglycan layer with lipoteichoic acids,10 which further contributes 
to the negative charge on the membrane for electrostatic interaction. The gram-negative bacteria have 
a thin peptidoglycan layer and an additional outer membrane layer that is composed of 
lipopolysaccharides that are anionic.11 It becomes a little difficult for the drugs to act on gram negative 
than gram positive due to more cell membrane layers. 
1.4 Polymer Overview12 
Polymers are macromolecular substances composed of groups of monomers which are linked 
to each other through controlled chemical process. This process is known as polymerization. The basic 
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requirement of the polymerization reaction is that one monomer must have the capability of being 
linked with the other monomer, that is, monomers must have a functionality of one or two. The 
physical and chemical properties of polymers are different from the monomers from which the 
polymer is formed. The difference in the molecular size is responsible for the variation in the physical 
properties between the polymer and the monomer. 
Homopolymers are a class of polymer which is made up from only one kind of monomer. A 
copolymer is made up of two or more different types of repeating units of monomers. Based on the 
particular arrangement of the repeating units along the polymer chain, there are several categories of 
copolymers such as statistical copolymers, alternating copolymers, graft copolymers, block 
copolymers, and random copolymers. 
1.5 Dendrimer Overview 
Dendrimers are highly branched globular star like structures that exhibit symmetry in their 
structure.13 Dendrimers consist of a central core from which identical fragments are built up to make 
a macromolecular structure. Based on the number of identical fragments grown from the center of the 
core, the generation of the dendrimer is defined.14 Dendrimers are in the nanosize scale and have 
narrow polydispersity and tunable surface entities.15 The end groups of the dendrimer will determine 
the solubility and reactivity of the dendrimer.13 These have gained importance as it is easier for the 
further functionalization of the end groups and can be used for various biomedical applications.16 
Currently, dendrimers have been used in target based drug delivery systems for the treatment of cancer, 
as antimicrobial agents, enzyme catalysis and surface engineering techniques. 
1.6 Host-defense peptides (HDPs)  
More exposure of the bacteria to conventional antibiotics has driven a way for the bacteria to 
develop resistance against most of the antibiotics available in the market. In recent times, bacteria have 
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developed resistance to the third-generation antibiotics available in the market. Researchers have 
focused on developing new antibacterial drugs that can combat bacterial resistance. Host-defense 
peptides (HDPs) may be an alternative strategy to the conventional antibiotics. HDPs are found in the 
innate system of human body and can act against pathogens. These HDPs show their mode of action 
by bacterial membrane disruption. It is known that HDPs are diverse in structure and can form helices, 
β-sheets, and extended structures. However, they frequently attain globally amphipathic nature when 
approaching the bacterial surface. The hydrophilic cationic groups direct the initial association of 
HDPs with the negatively charged bacterial membranes, whereas the hydrophobic groups assist in the 
penetration of HDPs into the bacteria, leading to rupture of the bacterial cell membranes. This kind of 
mechanism makes it difficult for bacteria to develop resistance. These characteristics have inspired 
researchers to design a wide range of HDP mimic that can act as antibacterial agents. However, HDPs 
are prone to proteolytic degradation, moderately active and are not cost effective. Thus, there has been 
considerable interest in developing peptidomimetics that mimic HDPs to overcome the 
disadvantages.17-18 Dr. Cai’s lab has focused on developing γ-AApeptides that mimic the mechanism 
of action of HDPs. γ-AApeptides are proved for their stability against enzymatic degradation and 
capability of forming secondary structures. 
1.7 γ-AApeptides  
The peptidomimetic oligomers have started to find important applications in chemical biology 
and biomedical sciences in the past two decades.19 Consisting of unnatural backbones, 
peptidomimetics could overcome obstacles associated with canonical peptides, including low 
bioavailability, susceptibility to proteolytic degradation, and limitation in chemodiversity.20 Thus, they 
could lead to the development of promising lead compounds and drug candidates. Indeed, 
peptidomimetics, such as β-peptides,21 α/β-peptides,22 peptoids,23-24 oligoureas,25 show capability to 
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mimic hierarchical structures of proteins, and are extensively studied for therapeutic applications. To 
expand the family of peptidomimetics and to facilitate their application in biomedical sciences, a new 
class of peptidomimetics - "γ-AApeptides" was developed.26-27 They are termed “γ-AApeptides”, as 
they are oligomers of γ-substituted-N-acylated-N-aminoethyl amino acids (Figure 1.1), similar to γ-
PNAs.28-30  
 
 
Figure 1.1. The chemical structure of α-peptide and γ-AApeptide. 
1.8 Outline of the Dissertation 
In this dissertation, we discuss the design, synthesis, and antibacterial efficacy of polymers, 
dendrimers and HDPs. 
 In chapter 2, we describe the synthetic design of the positively charged polycarbonates that 
shows activity against Gram-positive bacteria. 
In chapter 3, we discuss the design, synthesis of dendrimers and the appropriate amphiphilicity 
required to show broad spectrum antibacterial activity was evaluated. 
In chapter 4, we describe the design and development of a class of small antimicrobial 
molecules containing acylated reduced amide that has potent and broad spectrum antimicrobial 
activity. 
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In chapter 5, we discuss that bis-cyclic guanidine compounds could rationally adopt cationic 
amphipathic structures, and thus capable of mimicking HDPs and revive as a promising approach to 
combat bacterial resistance.  
  In chapter 6, we summarize the research findings and conclude the future directions of our 
research study. 
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CHAPTER 2: POLYCARBONATES WITH POTENT AND SELECTIVE 
ANTIMICROBIAL ACTIVITY 
 
Note to Reader 
Contents in this chapter have been previously published in Biomacromolecules, 2017, 18, 87-
95, and have been reproduced with the permission of the American Chemical Society (ACS). 
2.1 Introduction 
 
Bacterial infections pose a great threat to the public health.1 The World Health Organization 
(WHO) recently acknowledged that certain bacterial pathogens have acquired significant resistance to 
most of the commercially available antibiotics.2 In hospitals about 50-60% of the infections are caused 
by the lack of the sterility of medical devices used during surgeries, especially due to the contamination 
of notorious methicillin-resistant staphylococcus aureus (MRSA) strains. The Center for Disease 
Control (CDC) has reported that, 2 million people develop antibiotic resistance after antibiotic 
treatment and 23,000 people die due to the lack of proper treatment annually. Therefore, there is an 
escalating demand for the development of new antibacterial agents to combat the emerging resistance.3 
One promising approach to circumvent bacterial resistance is to develop derivatives of host-defense 
peptides (HDPs). Although antimicrobial mechanisms of HDPs are still in debate, it is generally 
believed that these cationic peptides fold into discrete secondary structures such as α- helices or β-
sheets upon binding to bacterial membranes, on which distinct hydrophobic and cationic patches are 
formed on the peptides.4 The cationic groups of HDPs bind to the negatively charged bacterial cell 
surface by electrostatic attraction, while the hydrophobic patch interacts with hydrophobic lipid bilayer 
of the bacteria, leading to penetration of the peptides. It is known that eukaryotic cells mainly contain 
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zwitterionic phospholipids such as phosphatidylcholine, phosphatidylethanolamine and 
sphingomyelin on their outer leaflet of membranes, whereas the negative charged lipids are largely 
sequestered in the inner leaflet of the membranes. As a result, these cells generally carry a net neutral 
charge on their surface. In contrast, both Gram-positive and Gram-negative bacteria bear a negative 
charge on their membrane surface due to the presence of phospholipids including phosphatidylglycine, 
phosphatidylserine and cardiolipin, making them more selective to cationic HDPs over mammalian 
cells due to charge attraction.5 In addition, Gram-positive bacteria have a thick peptidoglycan layer 
embedded with techoic and lipotechoic acids,6 whereas lipopolysaccharides (LPS) are an important 
component on the outer membranes of Gram-negative bacteria. These molecules all further contribute 
to the overall negative charge on the bacterial membranes. Another factor aiding to the selectivity of 
HDPs towards bacterial cells is that bacteria lack cholesterol in their membranes, whereas mammalian 
cells have 25% cholesterol or more in their membranes, which stabilizes their membrane integrity.7 
As such, disruption of bacterial membranes is relatively less challenging. The disruption of the 
bacterial cell membranes causes the leakage of the cytoplasmic contents and ultimately cell death.8 As 
this biophysical interaction lacks defined membrane proteins and other targets, development of 
resistance is believed to be more challenging.9 Therefore, HDPs and their derivatives have been 
extensively explored for antimicrobial development.10,10b However, HDPs have intrinsic drawbacks 
such as tedious and costly synthesis and purification. The pharmacokinetic properties and chemical 
instability of the peptides are other obstacles that hamper therapeutic applications of HDPs.7 
Moreover, HDPs exhibit moderate selectivity and are reported to be toxic toward mammalian cells.1 
One of the successful examples of HDPs is magainin II,11 which exhibits broad-spectrum but weak 
antimicrobial activity against bacteria. The synthetic analog of magainin, Pexiganan (also known as 
MSI-78) has shown much improved activity and entered Phase III clinical trials for the treatment of 
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diabetic foot ulcers. However, it failed eventually due to its moderate in vivo efficacy and high 
cost.12Due to drawbacks of HDPs, considerable effort has been extended to develop cationic 
antimicrobial polymers that mimic the function of HDPs, in the hope to supplement the potential 
application of HDPs. Compared to HDPs, polymers have some apparent advantages. The procedure 
for the preparation of polymers is generally very straightforward. Most of the polymer synthesis 
involves one pot polymerization reaction, which makes it easy to scale up to obtain products in large 
quantity.13 In addition, polymers are cost-effective. Examples of antimicrobial polymers include poly 
(α-amino acid)s,13 metallopolymers,14 nylon-3 polymers,15  polyacrylates,16 polyvinyl pyridines,17 
polystyrenes,18 polycarbonates,19 etc. Similar to HDPs, these polymers generally exert their activity 
by acting on bacterial membranes. 
Yang and Hedrick et al recently reported cationic antimicrobial polycarbonates containing 
quaternary ammonium salts.20,21 These quaternary ammonium moieties were introduced through post-
modification.22 Our previously reported antimicrobial peptidomimetics bear primary amino groups 
and show potent antimicrobial activity.10,10a  It is thus intriguing to study the antibacterial activity of 
polycarbonates bearing same groups. Herein, we report our investigation on the design and study of 
antimicrobial polycarbonates containing primary amino groups. Such a design eliminates the post-
modification step, and surprisingly, these polycarbonates are highly selective to bacteria, and show 
virtually no toxicity to blood cells under the tested condition. 
2.2 Materials and Methods 
Synthesis of the monomer 1 (Figure 2.1) 
The 5-methyl-2-oxo-1,3-dioxane-5-carbonyl chloride (MDC) was prepared according to the 
previous reported work by Yang and Hedrick.22 To synthesize the monomer 1, MDC (6.8 g, 38 mmol) 
was dissolved in 30 mL DCM in a 100 mL round bottom flask, to which a solution of Boc-protected 
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ethanolamine (6.15 g, 38 mmol) and TEA (7.85 mL, 57 mmol) in 10 mL DCM was added drop wise. 
The reaction was allowed to continue for 4 h in an ice bath. The solution was washed with 1 N HCl 
(100 mL×3), water (75 mL×3), brine (50 mL×1), and then dried over sodium sulfate. The solvent was 
removed in vacuo to give a yellow colored oil, which was further purified by flash chromatography 
(ethyl acetate/hexane 2:1) to give the final product monomer 1 (6.9 g, 22 mol, 60 %) as a white solid. 
 
Figure 2.1 Synthesis of the monomer 1. 
 
Synthesis of the monomer 2 (Figure 2.2) The monomer 2 was prepared according to the previous 
reported protocol by Yang and Hedrick.22 
 
Figure 2.2 Synthesis of the monomer 2. 
Synthesis of polycarbonate polymers. All the polymers were prepared in a similar fashion using ring 
opening polymerization21   (Figure 2.3 and Table 2.1). In order to synthesize Boc-protected random 
copolymer polycarbonate P6’ which was formed by the mixed monomers of 1 and 2, the initiator 
benzyl alcohol (0.05 g, 0.46 mmol) was dissolved in 10 mL of DCM in a N2 purged round bottom 
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flask. Then 20 eq of hydrophobic monomer 2 (2.31 g, 9.0 mmol) and 20 eq of hydrophilic monomer 
1 (2.8 g, 9.0 mmol) were added to the flask together (Scheme 2.3A), followed by the addition of 1-
(3,5-bis(trifluoromethyl)-phenyl)-3-cyclohexyl-2- thiourea catalyst (TU) (2 eq, 0.34 g, 0.9 mmol) and 
(1,8-diazabicyclo [5.4.0] undec-7- ene (DBU) (2 eq, 0.14 g, 0.9 mmol) base.  The reaction was allowed 
to stir for 4 h under nitrogen, and then quenched by addition of benzoic acid (1.1 eq, 0.06 g, 0.5 mmol). 
The other Boc-protected random copolymers were prepared in the similar way. 
For the synthesis of Boc protected di-block polymers P4’, the two monomers 1 and 2 were 
added in two batches separately in order to form two segments in the polymers (Scheme 2.3B). In 
brief, the Boc protected monomer 1 was first added to the reaction vessel in the presence of TU and 
DBU in 20 mL DCM and the reaction was allowed to run for 4 h under nitrogen. Subsequently, the 
hydrophobic monomer 2 was added and the reaction was allowed to continue for another 4 h. The 
reaction was quenched by benzoic acid at the end. 
Table 2.1 Structures of the synthesized polymers. abased on NMR integration; bbased on GPC. 
Compound 
Type of co-
polymer 
 
Hydrophobic 
units 
 
Hydrophilic 
units 
 
Molecular weight 
Theoretical Observeda PDIb 
P1 Single 0 20 4168 4168 1.05 
P2 Di-block 10 15 5653 5593 1.1 
P3 Random 10 10 4638 4588 1.08 
P4 Di-block 10 10 4638 4595 1.15 
P5 Random 15 10 5888 5864 1.1 
P6 Random 20 20 9168 9030 1.06 
P7 Random 15 15 6903 6917 1.13 
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P8 Random 20 10 7138 7075 1.05 
 
Figure 2.3 Synthesis of the amphiphilic polycarbonates. 
A, synthesis of random polymer P6’ and P6, in which the monomer 1 and 2 were added in one batch; 
B, synthesis of di-block polymer P4’ and P4, in which the monomer 1 and 2 were added in two batches. 
Dialysis. The polymers were dissolved in 2 mL methanol and dialyzed against methanol (dialysis 
tubing MWCO=3500) for three days, with methanol being replaced twice a day.13 
De-protection of Boc in the polymers. The solvent was evaporated and the products were treated 
with 50 % TFA in 10 mL DCM for 2 h. The solvent was removed in vacuo and the residues were 
dissolved in DMSO and dialyzed against methanol for three days. After methanol was removed, the 
samples were dissolved in 5 mL of water and lyophilized to give the final polymers P1-P8 as colorless 
sticky oils, which were characterized by 1H NMR and GPC subsequently (Table 2.1). 
MIC (Minimum Inhibitory Concentration)/Antimicrobial Activity. Minimum inhibitory 
concentration (MIC) was used to measure the efficacy of the synthesized polycarbonates against 
bacteria.23 MIC is defined as the lowest concentration of the compound by which it can completely 
inhibit the growth of the bacteria for a period of 20 h. Three clinically relevant Gram-positive strains, 
Methicillin-resistant S. epidermidis (MRSE, RP62A), Vancomycin-resistant E. faecalis (VREF, 
ATCC 700802), and Methicillin-resistant S. aureus (MRSA, ATCC 33591) were used in the assay. 
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Briefly, a single colony was isolated from the agar plate and allowed to grow in 4 mL TSB solution 
overnight in a digital shaking incubator at 37 °C. The following day the culture was diluted by 100-
fold and the diluted culture was shaken for 6 h in order for the bacteria to reach the mid-logarithm 
phase.  In a 96-well plate 50 µL of the polymer solution in 2-fold serial dilutions (50 µg/mL to 1.6 
µg/mL) were added to the wells. Next, aliquots of the bacterial solution (50 µL, 1 × 106 CFU/mL) 
were added to those polymer solutions, respectively, and the plate was incubated at 37 °C. After 20 h, 
the plate was read at 600 nm wavelength on a Biotek Synergy HT microtiter plate reader and the MIC 
values were determined. Results were repeated at least three times in duplicates each time.24 
Hemolytic Activity Study. To determine the selectivity of the polymers, the compounds were 
incubated with the human red blood cells and the HC50 for the compounds was calculated. HC50 is 
defined as the concentration that causes 50% hemolysis of the human red blood cells (hRBCs). 25,26,27 
In this assay, freshly drawn blood was centrifuged,, and erythrocytes were separated and washed a 
couple of times with PBS buffer, and the supernatant was removed. The polymer samples (50 µL) of 
various concentrations were made in a 96 well plate using 2-fold serial dilution technique. The 
erythrocytes were diluted to a final concentration of 5% (v/v) in PBS buffer. 50 µL of the erythrocytes 
diluted samples were added to the serial-diluted polymer solutions and incubated for 1 h at 37 °C. The 
96 well plate was centrifuged at 3500 rpm for 10 min, and 30 µL supernatant liquid was transferred to 
a new 96 well plate containing 100 µL of PBS in each vial. The absorbance of these solutions was 
taken at a wavelength of 540 nm. For this assay PBS was used as negative control and 0.1% Triton x-
100 was used as positive control. Hemolysis is calculated using the formula below: 
%hemolysis = [(Abs of Sample-Abs of PBS negative control)/ (Abs of positive Control-Abs of PBS 
negative control)] ×100 
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Bacterial Resistance Assay. MICs of the samples were determined by the method described above. 
After determination of the MIC, the bacterial solution from the well that contained the polymer at one-
half concentration of the MIC value was used to dilute to 1 × 106 CFU/mL. Next, 50 µL of this bacterial 
solution was added to the 50 µL of 2-fold serial-diluted polymer samples, and the new MIC was 
measured. This assay was repeated for 14 passages. If the polymer had virtually the same MIC after 
every passage it indicated that the polymer did not developed resistance in the bacteria.28 
Fluorescence Microscopy. DAPI (4’, 6-Diamidino-2-phenylindole dihydrochloride) and PI 
(Propidium iodide) were used in the assay.29,29b DAPI is the dye that stains all the dead and living 
bacteria, whereas the PI dye stains only the dead bacteria with damaged membranes as itself is not cell 
permeable and it has to  interact with the nucleic acids of the bacteria and fluorescing in bright red 
color.  Briefly, the bacteria were allowed to grow to the mid logarithmic phase and then incubated 
with the polymer P6 (6 µg/mL) at 37 °C for 3 h. The solution was centrifuged at 10,000 g for 10 min 
in an Eppendorf tube.  The supernatant was removed and the bacterial pellets were washed with PBS 
three to four times. PI (5 µg/mL) was added and incubated for 15 min in dark at 0°C. The excess of 
the dye was removed by PBS washes (×3). Next, the cells were incubated with DAPI (10 µg/mL in 
water) for 15 min in dark at 0 °C and excess of the dye was removed, followed by PBS washes (×3). 
The bacteria were then examined under oil-immersion objective (100×) by using the Zeiss Axio 
Imager Z1optical microscope.30 
Time Kill Assay. This assay determines bacterial killing kinetics for the polymer. Different 
concentrations of the polymer were incubated with bacterial suspension, at time intervals of 0 min, 10 
min, 30 min, 1 h, and 2 h. At these time points, 100 µL of the solution were taken and diluted 102 to 
104 times and then spread on respective agar plates for incubation at 37 °C. After 20 h, the bacterial 
colonies were counted. The assay was repeated at least three times.31 
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Dead Bacteria TEM. The control and the polymer treated bacterial samples were made in the similar 
way as in fluorescence microscopy assay. The samples were spread on 200-mesh copper grids and 
were left for 1 h for adsorption onto the grid, and stained by 1% uranyl acetate for 30 sec. The grids 
were analyzed at 60 kV with FEI Morgagni 268D TEM instrument.29b 
2.3 Results and Discussion 
Synthesis of cationic polycarbonate polymers containing primary amino groups. 
Yan and Hedrick et al developed antimicrobial polycarbonates containing quaternary 
ammonium salts20 that show good activity towards a range of Gram-positive bacteria. However, the 
formation of quaternary ammonium salts involves post-modification. Based on our previous findings, 
we envisioned that polycarbonates with primary amino groups should also be active and maybe even 
more selective toward bacteria. As such, we designed and synthesized a series of such type of polymers 
(P1-P8) and investigated their antibacterial activity. The synthesis is straightforward as described 
earlier. The polymers are well characterized by NMR and GPC (Table 2.1, Figure 2.4, and supporting 
information).  
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Figure 2.4 General representation of 1H NMR for polycarbonates. 
Antimicrobial activity of the polymers. 
In order to understand the effect of sequence composition on the antimicrobial activity of the 
polymers, we synthesized both random (in which hydrophilic and hydrophobic monomers were 
randomly arranged) and diblock (in which there are defined hydrophobic and hydrophilic segments) 
polycarbonate copolymers. These amphiphilic polycarbonate polymers (P1 - P8) were tested for their 
antimicrobial activity against three different Gram-positive bacterial strains, Methicillin-resistant S. 
epidermidis (MRSE, RP62A), Vancomycin-resistant E. faecalis (VREF, ATCC 700802), and 
Methicillin-resistant S. aureus (MRSA, ATCC 33591), all of which are clinically relevant threatening 
strains (Table 2.2). The polymer P1, containing only hydrophilic amino groups but no hydrophobic 
groups, failed to show any activity against the bacterial strains under tested concentrations. In contrast, 
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the other polymers containing both hydrophilic and hydrophobic groups all show good antibacterial 
activity. This data clearly demonstrates that although positive charges are necessary for initial 
recognition and selective association with bacteria, cationic groups alone are not sufficient for 
bacterial killing. Hydrophobic groups are critical for membrane interaction and disruption, and 
ultimate death of the bacteria.32 The diblock copolymers P2 and P4, differing in the number of 
hydrophobic groups, show similar activity against three different Gram-positive bacterial strains. We 
hypothesized that diblock copolymers may form stable nanomicelles structures in solution, in which 
their hydrophobic groups are sequestered, leading to comparable antimicrobial activity. To test our 
hypothesis, we synthesized the random polymer P3 that contains same number of hydrophobic and 
hydrophilic groups as P4. Consistent to our hypothesis, the antibacterial activity of P3 was better than 
P4. Although the activity against VREF remained the same for both P3 and P4, P3 exhibited good 
activity of 2.2 µM and 2.6 µM against MRSA and MRSE, indicating it is 2-fold more potent than P4 
toward these two strains. We thus focused on the study of activity of random polymers, and further 
investigated how the activity of this type of polymers was related to the ratio of hydrophobic and 
hydrophilic groups. With the same number of hydrophilic groups, increasing the number of 
hydrophobic groups enhanced antimicrobial activity, as seen for polymers P3, P5 and P8. Containing 
20 hydrophobic groups, P8 exhibited an excellent activity of 0.7 µM, 1.4 µM and 2.8 µM against 
MRSA, MRSE and VREF respectively. Similar trend was also revealed with the change of positively 
charged groups. Containing 20 hydrophilic and 20 hydrophobic groups, the random copolymer P6 
showed potent activity against all three bacterial strains, with the activity of 0.17 µM, 0.55 µM and 
0.55µM against MRSA, MRSE and VREF respectively. It is reasonable because the sequences 
containing more hydrophobic and hydrophilic groups have stronger interaction with bacterial 
membranes. The findings again suggested that both cationic and hydrophobic groups are essential for 
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the development of antimicrobial polymers, and their arrangement in the sequences plays a very 
important role.    
We next conducted hemolytic assays to evaluate the selectivity of the polymers (Table 2.2). 
Surprisingly, none of the polymers was toxic at the tested condition even up to 1 mg/mL. The most 
potent polymer P6 displayed a selectivity of at least 600fold for MRSA. The results indicate that these 
polymers are highly selective toward bacteria and thus hold great promise for the development of 
potent antibacterial agents. 
  Table 2.2 Antibacterial activity of polycarbonates.                                    
Compound 
Type of  
co-polymer 
 
Hydro 
phobic 
units 
 
Hydro 
philic 
units 
 
Gram Positive, µg/mL (µM) Hemolysis 
(HC50) 
(µg/mL) 
Selectivity  
Index  
(HC50/MIC of 
MRSA) MRSA MRSE VREF 
P1 Single 0 20 >50 >50 >50 >1000 >20 
P2 Di-block 10 15 25 (4.47) 25 (4.47) 25 (4.47) >1000 >60 
P3 Random 10 10 10 (2.2) 12 (2.6) 25 (5.45) >1000 >100 
P4 Di-block 10 10 25 (5.44) 20 (4.35) 25 (5.44) >1000 >40 
P5 Random 15 10 10 (1.7) 20 (3.4) 20 (3.4) >1000 >100 
P6 Random 20 20 1.6 (0.17) 5.0 (0.55) 5.0 (0.55) >1000 >625 
P7 Random 15 15 10 (1.45) 20 (2.89) 20 (2.89) >1000 >100 
P8 Random 20 10 5 (0.7) 10 (1.4) 20 (2.8) >1000 >200 
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Morphology of polymers. 
  As we predicted that the antimicrobial activity of the polymers is related to their 
nanomorphology, we next conducted Transmission Electron Microscopy (TEM) experiment to test 
our hypothesis.  As expected, most of the polymers formed into micelles in water with the size ranging 
from 80 to 200 nm (Figure 2.5). We particularly compared the morphology of P3, P4 and P6. These 
micelles show hydrophobic cores and hydrophilic coronas.  The size of the particle increases as the 
hydrophobic and hydrophilic entities increase, as observed for P3 and P6 (Figure 2.5A and 2.5B). 
The diblock copolymer P4 (Figure 2.5C) was found to be larger than the random copolymer P3 
(Figure 2.5A) which comprised of same number of hydrophobic and hydrophilic entities. This may 
be because P4 forms more stable core-shell micelle structure due to its diblock structure, and therefore 
more sequences can self-assemble together to form large-sized micelles. In the contrast, although P3 
also contains both hydrophobic and hydrophilic groups, their random arrangement renders less ability 
of the sequences to assembly into defined nanostructure. This is also demonstrated by their zeta 
potentials (Table 2.3). P4 has a zeta potential of 58.98 mv, which is much larger than P3 and P6. This 
is consistent to our hypothesis, that random polymers are more active to bacteria than diblock polymers 
as they can quickly dissociate into smaller aggregates or single molecules, and as a result, they 
effectively interact and disrupt bacterial membranes. 
 
       A: P3                            B: P6                            C: P4 
Figure 2.5 TEM micrographs showing the size of the polycarbonates. 
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Table 2.3 Size and Zeta potential of polycarbonates. 
Compound 
Type of 
co-polymer 
 
Hydrophobic 
units 
 
Hydrophilic 
units 
 
Z-Average (d. nm) Zeta Potential (mV) 
P1 Single 0 20 255.7 44.2 
P2 Di-block 10 15 154.0 54.7 
P3 Random 10 10 81.20 26.1 
P4 Di-block 10 10 212.0 58.9 
P5 Random 15 10 209.0 31.7 
P6 Random 20 20 288.4 16.1 
P7 Random 15 15 328.7 9.70 
P8 Random 20 10 435.1 7.73 
 
Antimicrobial mechanism 
The mode of action of the polymers against bacteria was initially evaluated by fluorescence 
microscopy using double staining method (Figure 2.6).33 The most potent sequence P6 was selected 
for the study. The control, which is just MRSA bacteria themselves, showed blue fluorescence under 
DAPI channel (a1). They were not observed under PI channel (a2) because their membranes were 
intact, and therefore they could not be stained by DAPI. In contrast, after MRSA were treated with 
P6, they were stained by both PI and DAPI (b1, b2), and observable under both channels, indicating 
MRSA membranes were disrupted. 
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Figure 2.6 Fluorescence micrographs of MRSA treated with 10 µg/mL of P6. 
The mechanism of action was further supported by TEM (Figure 2.7), under which the 
morphology of untreated MRSA and the polymer P6 treated MRSA was revealed. The control 
(bacteria without treatment) show spherical shape with intact cell membranes (Figure 2.7A), a typical 
morphology of MRSA. However, after the treatment of bacteria with P6, most bacterial lost their 
spherical morphology. Instead, the leakage of the contents from the bacterial cells was observed 
(Figure 2.7B). These results suggest that bacterial membranes were disrupted by the polymer P6. 
 
       A                                   B 
Figure 2.7 TEM micrographs of Control MRSA(4A) and MRSA treated with P6 - 10 µg/mL (4B). 
a2 
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Based on antimicrobial activity and nanomorphology of the polymers, we propose their 
mechanism of action (Figure 2.8). The polymers are initially believed to exist in micelle conformation 
in solution. As polymers approach the bacterial surface, due to change in the electrostatic interactions, 
the polymers lose their stability and start to dissociate into small entities or free polymer chains, which 
could bind to the bacterial membranes more effectively. The free polymer chain penetrates the surface 
of the bacteria due to its amphipathic nature and ultimately disrupts the bacterial membrane, leading 
to bacterial cell death. 
 
Figure 2.8 Proposed mechanism of action of the polymers on Gram-positive bacteria. 
Bacterial Kinetics Assay. 
To determine the time of action and efficacy of the polymers, the most potent polymer P6 was 
chosen for time kill study (Figure 2.9). Cell viability was determined by the colony county method 
on agar plate at regular intervals of 30 min, 1 h, 2 h, 3 h, 6 h, 9 h,12 h and 24 h. At the concentration 
of 50 µg/mL and 25 µg/mL, the bacteria were completely eradiated after 6 h, suggesting that the 
polymer has the bactericidal mechanism and the action is rapid. 
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Figure 2.9 Time kill study of P6 for MRSA. 
 
Drug Resistance Assay of polymers. 
The TEM and florescence microscopy suggest the polymers act by membrane disruption 
mechanism on the bacteria. Under this mechanism, it is accepted that the bacteria are less prone to 
develop resistance. To evaluate the probability of the polymer to induce resistance in bacteria, drug 
resistance study was conducted for the most potent compound P6 against MRSA. As shown in the 
Figure 2.10, the MIC values were virtually constant even after 14 passages, indicating that the bacteria 
do not develop resistance readily towards the polymer. 
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Figure 2.10 Drug Resistance Study of P6 for MRSA. 
2.4 Conclusion 
We reported the development of potent and highly selective antimicrobial polycarbonate 
polymers containing primary amino groups. Our results suggest that amphiphilic nature is necessary 
for bacterial killing, and random block polymers are more potent than diblock polymers, possibly due 
to stable nanostructures of diblock polymers which prevent them from interacting with bacterial 
membranes more effectively. The fluorescence microscopy and the TEM data suggest that these 
polymers have the mechanism of action of bacterial membrane disruption. Remarkably, these 
polymers are highly selective towards bacterial cells and show no discernable hemolytic activity. In 
vivo study of these polymers on the mouse model to evaluate their efficacy is currently underway.  
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CHAPTER 3: LIPIDATED DENDRIMERS AS POTENT AND SELECTIVE BROAD 
SPECTRUM ANTIBACTERIAL AGENTS 
 
3.1 Introduction 
The resistance developed by bacteria against antibiotics have contributed to the sharp rise in 
illness and deaths that were once curable.1 Conventional antibiotics are generally small molecules that 
exert their activity by targeting specific cellular nucleic acids and proteins, or cell wall enzymes of 
bacteria. Bacteria will likely develop mutations rapidly on the targets upon prolonged antibiotic 
treatment, leading to the development of drug resistant bacterial strains.1 In order to combat the 
emerging resistance, research efforts have been focused on developing host-defense peptides (HDPs) 
as bacteria are believed to have less probability to develop resistance to HDPs due to their distinct 
antimicrobial mechanisms.2 It is known that HDPs are naturally occurring peptides that are rich in 
cationic and hydrophobic residues. Despite the diversity in three-dimensional structure, upon 
association with the bacterial membranes, HDPs generally obtain a globally amphipathic structure 
which is critical for the membrane action on bacteria.3 The interaction  occurs considerably selectively 
for bacteria as the outer leaflet of membranes of the bacteria is predominantly rich in negatively 
charged phospholipids.4 In addition, in Gram-positive bacteria, techoic acids or lipo-techoic acids are 
frequently identified on the peptidoglycan layer, whereas lipopolysaccharides are common 
components on the outer membranes of Gram-negative bacteria.5 These negative charges greatly 
contribute to the initial attraction of the catatonically charged HDPs onto the bacterial membranes. 
Subsequently, the hydrophobic patches of the HDPs help to further penetrate into the bacterial 
membranes through hydrophobic interactions with phospholipids. In contrast, the outer surface of 
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mammalian cell membranes is largely zwitterionic as they are dominated by neutral phospholipids 
such as cholesterol, phosphatidylcholine, and sphingomyelin, while their negatively charged 
phospholipids are essentially found in the inner leaflet of membranes. As such, HDPs have less 
probability to interact with mammalian cells compared with bacteria, which is believed to account for 
at least a significant part of the selectivity of HDPs.6  As such membrane action lacks specific 
molecular targets, it is generally believed that HDPs are less prone to development of antibiotic 
resistance.7 
Owing to the abovementioned advantages, HDPs have received notable attention as a new 
generation of antimicrobial agents combating antibiotic resistance. However, there are still limitations 
of HDPs, which include low-to-moderate activity, potential high cost of manufacturing, proteolytic 
degradation etc.8 It is conceivable that the antimicrobial agents which can mimic the mechanism of 
HDPs but with enhanced selectivity and antimicrobial activity will be one viable strategy for antibiotic 
development. To date, unnatural peptidomimetics such as β-peptides,9 peptoids,10 oligoureas,11 
AApeptides,12,12f  have been developed to mimic HDPs and target a  wide range of bacterial strains. 
These peptidomimetics are generally more active than natural HDPs, however, they still suffer from 
potential high manufacturing cost and difficulty in scale-up.13 Another alternative approach is to 
develop cationic antimicrobial polymers such as poly (α-amino acid)s,14 nylon-3 polymers,15 
polyacrylates,16 polycarbonates,17 and dendrimers such as PAMAM,18 poly(propylene imine),19 etc.  
Dendrimers are highly branched globular structures that exhibit symmetry in their structure. They 
consist of a central core from which identical fragments are built up to make star-like macromolecular 
structures.20 Compared with linear polymers, dendrimers are normally in the nanosize scale and have 
narrow polydispersity, uniform nanomorphology, and tunable surface entities.21 The terminal groups 
of the arms of the dendrimer determine its solubility and reactivity,20 and are also available for further 
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modification. Thus, dendrimers have attracted interest in exploring their potential application in the 
biomedical and materials sciences.22 For instance, dendrimers have been used in targeted drug delivery 
systems for the treatment of cancer,23 as antimicrobial agents,24 enzyme catalysis and surface 
engineering techniques.25  
Different attempts have been done to synthesize dendrimer compounds by introducing 
functional groups pertaining to antimicrobial activity, e. g., poly(amidoamine) dendrimers with 
quaternary ammonium salts.26 Similarly, lysine dendrimers were synthesized by coupling with other 
peptides and confer activity against bacteria.27 Herein, we are presenting dendrimers that encompass 
lysine amino acid to present a multicharged cationic surface and bear a hydrophobic domain which is 
composed of different lengths of C tails.  We evaluated the desired amphiphilicity of the dendrimers 
to show antibacterial activity and evaluated their activity and mechanism of action.  The synthesis of 
these dendrimers is less tedious and can be easily scaled up by solid phase peptide synthesis technique 
and are cost effective, augmenting their potential in vitro and in vivo applications.  
3.2 Results & Discussion 
Solid phase Synthesis of lipidated dendrimers 
Lipidated dendrimers were synthesized on Rink amide resin by the standard Fmoc chemistry 
protocol used for the synthesis of peptides (Solid phase peptide synthesis). 20% piperidine in DMF 
was used to remove the Fmoc protecting group in every coupling cycle which was followed by the 
coupling of 2 equiv of the desired monomer that is to be attached on the beads with 4 equiv of HOBT 
(1-hydroxybenzotriazole monohydrate) and DIC (diisopropylcarbodiimide) in DMF for 4 h.28 The 
coupling reaction time was increased to 6-8 h upon increasing the number of generations of the 
dendrimer. In order to synthesize lipidated dendrimer, initially MTT-Lys(Fmoc)-OH was attached 
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onto the rink amide resin. After having the monomer attached to the solid support, the MTT (4-
Methyltrityl) protecting group was selectively removed under 2% TFA.  
To synthesize D-A type of dendrimer, the carbon tail is attached to the first monomer and later 
followed by the standard Fmoc coupling chemistry with the Fmoc-Lys(Fmoc)-OH monomer. In order 
to synthesize D-B type of dendrimer, after removing the MTT protecting group, Dde-Lys(Dde)-OH 
monomer was coupled on to the first monomer on the solid support, followed by the deprotection of 
the Dde protecting group with hydroxyl amine (1.8 mmol) and imidazole (1.35 mmol) which was 
suspended in 5 mL NMP solution and was sonicated until dissolved.  A ratio of 5:1 NMP and DMF 
solution was added on to the solid support and ran for 2h for deprotection of Dde.29 To each of the two 
unprotected amines, one C16 carbon tails was attached. Later the standard Fmoc coupling chemistry 
with the Fmoc-Lys(Fmoc)-OH monomer was done until the desired dendrimer was obtained. 
The lipidated dendrimers were cleaved from the solid support in 50:48:2 TFA/CH2Cl2/TIS 
(triisopropylsilane) for 2 h. The solvent was evaporated, and the dendrimers were purified by Waters 
HPLC system monitored at 215 nm and the desired product peaks were collected and lyophilized. By 
Bruker AutoFlex MALDI-TOF mass spectrometer, the product peaks were analyzed and the 
dendrimer that has the desired molecular weight were separated and further used for antimicrobial 
activity assays. 
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Figure 3.1 Solid phase Synthesis of D-A and D-B dendrimers. 
 
Figure 3.2 Solid phase Synthesis of a series of D-A dendrimers. 
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Figure 3.3 Solid phase Synthesis of a series of D-A-2 dendrimers. 
 
 
Figure 3.4 Solid phase Synthesis of a series of D-B dendrimers. 
 
 
Dendrimer n 
D-A-2a 12 
D-A-2b 10 
D-A-2c 8 
D-A-2d 6 
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Antimicrobial and Hemolytic activity 
Table 3.1 The Antibacterial and Hemolytic Activity of Lipidated Dendrimers. 
 
In order to determine the amphiphilicity of the dendrimers that was required to exhibit broad 
spectrum antimicrobial activity a series of dendrimers were synthesized. These dendrimers were 
grouped as two types D-A and D-B, which differ mainly in the number of C16 carbon tails present. 
The synthesized amphiphilic dendrimers (D-A-1 to D-A-4 and D-B-1 to D-B-4) were tested for their 
antimicrobial activity against three clinically threatening Gram-positive bacterial strains, methicillin-
resistant S. epidermidis (MRSE, RP62A), vancomycin-resistant E. faecalis (VREF, ATCC 700802), 
and methicillin-resistant S. aureus (MRSA, ATCC 33591), and two Gram-negative bacterial strains, 
E. coli (ATCC 25922), P. aeruginosa (ATCC 27853). Primarily, comparing the two major types of the 
dendrimers synthesized, D-B failed to show activity (D-B-1 to D-B-4) against any bacterial strains. 
The highest concentration that was used for testing the antimicrobial activity was 25 µg/mL. Even 
upon doubling the hydrophilic pattern from D-B-1 to D-B-4, the dendrimers did not exhibit activity. 
 
 
Dendrimer 
 
 
MW 
 
Terminal  
amine  
groups 
Carbon 
 tail  
length 
Gram positive 
bacteria (µM) 
Gram negative     
bacteria (µM) 
 
Hemolysis  
(HC50,) 
µg/mL) 
 
Selectivity  
index 
of MRSA 
(HC50/ MIC) 
MA MRSE VREF E. COLI P. A 
D-A-1 512 2 16 5.8 2.9 5.8 - - 125 21 
D-A-2 768 4 16 0.9 0.9 0.9 3.9 3.9 >250 167 
D-A-3 1280 8 16 1.17 1.17 1.17 4.6 4.6 >250 84 
D-A-4 2306 16 16 - - - - - -  
D-A-2a 740 4 14 2.02 2.02 2.02 - - 125 84 
D-A-2b 712 4 12 4.2 2.1 4.2 - - 125 21 
D-A-2c 684 4 10 - - - - - -  
D-A-2d 656 4 8 5.8 2.9 5.8 - - -  
D-A-1 512 2 16 0.9 0.9 0.9 3.9 3.9 125 21 
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This might be because of the excess hydrophobic nature obtained from the two carbon tails in the 
dendrimers D-B. Our hypothesis is that the two carbon tails are sterically hindering the amine groups 
by folding over and blocking their interaction on to the membrane of the bacteria In contrast, the 
dendrimer D-A-1 which had only two terminal amine groups and one C16 carbon tail exhibited good 
antibacterial activity against Gram-positive bacterial strains.  The activity was reported to be 6-3 
µg/mL against MRSA and E. faecalis and 3-1.5 µg/mL against MRSE bacterial strain. Excited by the 
positive results, D-A-2 was synthesized which had twice the hydrophilic nature and same hydrophobic 
nature as D-A-1. To our delight, we found that the dendrimer was active against both Gram-positive 
and Gram-negative bacterial strains with an activity of 1.5-0.75 µg/mL against Gram-positive strains 
and 6-3 µg/mL against Gram-negative strains. Further, D-A-3 and D-A-4 dendrimers were synthesized 
by increasing the terminal cationic amine groups to 8 and 16 and having one C16 hydrophobic carbon 
tail respectively. Unexpectedly, the D-A-3 activity reduced against both bacterial strains when 
compared to D-A-2. The activity was reported to be   3-1.5 µg/mL against MRSA, MRSE, and VREF 
Gram-positive strains and 12-6 µg/mL against E. coli and P.A Gram-negative strain. D-A-4 was found 
to be inactive against both bacterial strains. From the above results, we were able to identify the 
optimum hydrophilic and hydrophobic nature that was required to show potent and broad-spectrum 
activity. 
To evaluate further on the required hydrophobicity of the dendrimers to display the activity, a 
series of dendrimers (D-A-2a to D-A-2d) were synthesized which had the structure similar to the most 
active dendrimer D-A-2 but varying in the length of the carbon tail; D-A-2a, D-A-2b, D-A-2c, D-A-
2d had 14, 12, 10, 8 carbon tail length respectively. The dendrimers D-A-2a, D-A-2b were reported to 
be active against only Gram-positive bacteria and the activity ceased as the length of the carbon tail 
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decreased from D-A-2c and D-A-2d dendrimer (Table 1). From the results, it is evident that a 
minimum length of C16 hydrophobic tail is necessary for the broad-spectrum activity of dendrimers. 
In order to know the selectivity and further application of the dendrimers, a comparison of the 
antimicrobial and hemolytic data study was found to be crucial. Therefore, hemolytic study was 
conducted and the results were analyzed for the active dendrimers. The hemolysis for the most active 
dendrimer D-A-2 was reported to be >250 µg/mL which proves that the dendrimer was more selective 
to the bacterial cell membrane than the human cellular membrane. D-A-2 was further reported to be 
165 times more selective towards MRSA than the human cells. 
Mechanism of Action 
These above findings suggest that cationic and anionic groups are required for the dendrimer 
to exhibit antibacterial activity. An appropriate ratio of both the groups are required to exhibit potent 
and broad-spectrum activity which has been evaluated and reported. We hypothesize that our 
dendrimers exhibit antibacterial activity by disrupting the cellular membrane similar to the 
antibacterial action of HDPs. The cationic amine groups on the dendrimer were hypothesized to bind 
to the negative teichoic acid groups on the bacterial surface and having made an interaction, the 
hydrophobic carbon tail helps in the penetration of the dendrimer into the bacterial membrane resulting 
in the leakage of the cellular contents of the bacteria and eventually leads to bacterial cell death. 
In order to confirm our proposed hypothesis for the mechanism of action, florescence microscopy 
(FM) and transmission electron microscopy (TEM) experiments were done for the controlled bacteria 
and the drug treated bacteria. As the dendrimer displayed broad spectrum activity, a Gram-positive 
strain (MRSA) and a Gram-negative strain (E. coli) were used for the FM and TEM study.  
In FM assay, two types of dyes were used to stain the bacteria. 4′,6-diamidino-2-phenylindole 
(DAPI) is a membrane permeable dye that can stain all the cells as it binds to the DNA double strand; 
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whereas propidium-iodide (PI) is the non-membrane permeable dye that can stain only the dead cells, 
as it interacts with the nucleic acids of the bacteria and gives a bright red fluorescent complex. So, PI 
can interact only when the cell membrane of the bacteria is disrupted. Hence by this method we can 
determine if the dendrimers display their action by membrane disruption. The most active dendrimer 
D-A-2 was used for the FM study to evaluate its mechanism of action. From Figure 3.5 & 3.6, it is 
clearly evident that D-A-2 dendrimer was able to disrupt the membrane of MRSA and E. Coli 
respectively as PI stain was seen with the bacteria treated with D-A-2 but not with the control bacteria. 
This indicates that dendrimer D-A-2 showed its bactericidal action against Gram-positive and Gram-
negative bacteria by membrane disruption technique. 
 
Figure 3.5 Fluorescence micrographs of MRSA treated with 10 µg/mL of D-A-2 for 2 h. 
(C1) Control MRSA, DAPI stained, no treatment with D-A-2;  
(C2) Control MRSA, PI stained, no treatment with D-A-2;  
(D1) MRSA, DAPI stained, treated with the D-A-2;  
(D2) MRSA, PI stained, treated with the D-A-2. 
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Figure 3.6 Fluorescence micrographs of E. Coli treated with 10 µg/mL of D-A-2 for 2 h. 
(C1) Control E. Coli, DAPI stained, no treatment with D-A-2;  
(C2) Control E. Coli, PI stained, no treatment with D-A-2;  
(D1) E. Coli, DAPI stained, treated with the D-A-2;  
(D2) E. Coli, PI stained, treated with the D-A-2. 
In order to further prove our hypothesis of the dendrimer mimicking the mechanism of action of HDPs, 
TEM microscopy images were used to analyze the morphology for the drug treated and non-drug 
treated bacteria. Figure 3.7 & 3.8, clearly shows the membrane disruption when treated with the 
dendrimer D-A-2 for Gram-positive and Gram-negative bacteria respectively. 
 
Figure 3.7 TEM micrographs of MRSA treated with 10 µg/mL of D-A-2 for 2 h. 
(a)        Control MRSA, no treatment with the drug;  
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(b)        MRSA treated with D-A-2, image representing the initial rupture of the membrane;  
(c)      MRSA treated with D-A-2, image representing the damage of the cell membrane, cell rupture. 
 
Figure 3.8 TEM micrographs of E. Coli treated with 10 µg/mL of D-A-2 for 2 h. 
(a) Control E. coli, no treatment with the drug;  
(b)  E. coli treated with D-A-2, image representing the initial rupture of the membrane;  
(c)  E. coli treated with D-A-2, image representing the damage of the cell membrane, cell rupture. 
Bacterial Kinetic Study 
To future investigate the time of bactericidal action of the dendrimers, bacterial kinetics assay 
was conducted. The most active dendrimer D-A-2 was taken and the time required to show its 
bactericidal action was analyzed for Gram-positive and Gram-negative bacteria. Colony forming units 
of the Gram-positive and Gram-negative bacteria on the agar plate were counted for three different 
concentrations (50 µg/mL, 25 µg/mL, 12.5 µg/mL) of the D-A-2 treated bacteria and the control 
bacteria at regular intervals of 10min, 30 min, 1 h, 2 h. From Figure 3.9 & 3.10, it is clearly evident 
that at the concentration of 50 µg/mL, 25 µg/mL 12.5 µg/mL, the Gram-positive bacteria MRSA were 
eradicated completely after 1h, whereas the Gram-negative bacteria, E. Coli was eradicated after 2h 
at the concentration of 50 µg/mL, 25 µg/mL 12.5 µg/mL. This delay in bactericidal action on the 
Gram-negative bacteria might be due to the presence of the extra outer membrane layer, which is not 
present in the Gram-positive bacterial strains.  
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Figure 3.9 Time kill study of D-A-2 against MRSA 
 
 
Figure 3.10 Time kill study of D-A-2 against E. Coli 
Bacterial Biofilm Assay 
The infections caused by biofilms are a great threat to human life. Recent reports have shown 
that 80% of the bacterial infections are caused due to biofilms.30 Bacterial biofilm has become a severe 
problem specially in the cases of patients who suffer from infections that occur from the antibiotic 
resistant bacteria.31 Biofilms formed by MRSA and E. Coli have become major concern in hospitals 
as they contaminate the surgical tools and organ catheters.32 Therefore, developing new drugs that act 
against biofilm formation has become a major concern to treat bacterial infections. Thus, we analyzed 
the biofilm inhibiting efficiency of the most active dendrimer D-A-2 against MRSA and E. Coli. As 
shown in Figure 3.11, at 0.17 μg/mL, D-A-2 was able to inhibit 85% of biofilm formation of E. Coli 
and was able to completely eradicate the biofilm formation of MRSA. At the concentration of 0.8 
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μg/mL, D-A-2 was able to eradicate biofilm formation of E. Coli completely. The above stated results 
confirm that the dendrimers can act as biofilm inhibitors. 
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Figure 3.11 Biofilm study of D-A-2 against MRSA and E. Coli. 
3.3 Materials and Methods 
Antimicrobial Assay. Twelve synthesized lipidated dendrimers were tested against different strains 
of bacteria to determine their Minimum inhibitory concentration (MIC). Three clinically threatening 
Gram-positive bacterial strains including methicillin-resistant S. epidermidis (MRSE, RP62A), 
vancomycin-resistant E. faecalis (VREF, ATCC 700802), and methicillin-resistant S. aureus (MRSA, 
ATCC 33591) and two Gram-negative bacterial strains, E. coli (ATCC 25922), P. aeruginosa (ATCC 
27853) were tabbed for testing. A serial dilution method was performed for determining the 
antimicrobial activities. In a 4ml of TSB solution a single colony of bacteria was grown and incubated 
at 37°C overnight after which the cultured bacteria were diluted by 100-fold and were shaken until 
their mid logarithmic phase was obtained. 50μL of medium containing different concentrations of the 
lipidated dendrimers was made in each vial of the 96 well plate. 50μL of aliquots of bacterial 
suspension is added to the medium with different drug concentrations. The 96 well plate was incubated 
at 37 °C overnight and the cell growth was monitored using Biotek synergy HT microtiter plate reader 
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under the 600nm wavelength absorbance. The assay was repeated two times and showed comparable 
results.33,33b,34 
Hemolysis Assay. The selectivity of the lipidated dendrimers was determined through hemolysis 
assay. To perform this assay fresh K2EDTA treated human red blood cells (hRBCs) were centrifuged 
at 1000g for 10 minutes. The step was done three times until the supernatant was clear, then the desired 
suspended erythrocytes were collected and washed with PBS buffer a couple of times. The collected 
RBC were then diluted into 5% v/v suspension. From the diluted solution 50 μL was taken and added 
to the already prepared serially- diluted lipidated dendrimer solutions and were left for incubation at 
37 °C for 1 hr. The incubated solutions were centrifuged at 3500 rpm for 10 minutes. To measure the 
absorbance, 30 μL of supernatant was diluted with 100 μL of PBS and absorbance at a wavelength of 
540 nm and 410 nm was recorded. Selectivity of the lipidated dendrimers (% Hemolysis) was then 
calculated by applying the formula   % hemolysis = (Abs sample − Abs PBS)/ (Abs Triton − Abs PBS) 
× 100%, where PBS was used as a negative control and 0.1% Triton x-100 was used as a positive 
control. Results were repeated two times with duplicates each time.35 
Fluorescence Microscopy. To assess whether the lipidated dendrimers acts on the bacterial membrane 
or not, a double staining florescence microscopy assay was used. Both, 6-diamidino-2-phenylindole 
dihydrochloride (DAPI) and propidium iodide (PI) dyes were selected as fluorophores to differentiate 
between the dead bacterial cells and viable cells, DAPI is capable of staining both live and dead cells 
but PI can only stain dead cells with damaged membrane cell due to its impermeable nature through 
the membrane. The bacteria were grown to mid logarithmic phase and were incubated with lipidated 
dendrimers at 37 °C for 2 h, the mixture was centrifuged at 1000g for 10 min. Once the bacterial pellets 
were collected and washed with PBS three to four times. They were subsequently incubated with PI 
(5 μg/mL) in the dark for 15 min at 0 °C, the excessive PI was rinsed using PBS several times. Lastly, 
48 
 
the cells were incubated with DAPI (10 μg/mL) for 15 min on ice and the excess DAPI was removed 
by washing with PBS buffer. After the samples were ready,10 μL of the bacteria were used for testing 
under Zeiss Axio Image Zloptical microscope using 100× oil-immersion objective.35 
Time kill study. The kinetic assay of the lipidated dendrimers was tested against MRSA and E. COLI. 
The bacteria were grown to midlogarithmic phase in TSB medium and then diluted into 106 CFUmL-
1 suspensions. Different concentrations of the lipidated dendrimers were then added to the diluted 
suspensions and incubated for 10 min, 30 min, 1 h, and 2 h, respectively. After incubation, the mixture 
was diluted into 102 to 104 times, then dispersed on TSB agar plates and incubated overnight at 37 °C. 
The colonies on the plates were counted and graphed against colony forming unit of bacteria and 
incubation time.36  
TEM. Similar procedure was used to grow the bacteria to mid logarithmic phase as incase of MIC 
study. Two samples were made, one batch has only bacteria and the other batch was the bacteria treated 
with D-A-2. Samples were incubated at 37 °C for 2 h and the solution was centrifuged at 1000g for 
10 min. Bacterial pellets were collected at the bottom of the tube. Pellets were washed with PBS three 
to four times before dissolving in DMSO to a 10-6 M.37 A drop of the solution was added on the carbon-
coated Cu grid and the excess sample was wiped off with the filter paper to avoid any aggregation. 
The grid was then left for 30 min on the bench top so that the sample can be absorbed onto the grid. 
Later the grid was washed with acetonitrile and left in oven for few minutes to remove any further 
traces of the solvent. The samples on the grids were analyzed and images were taken with FEI 
Morgagni 268D TEM instrument.38,39 
Biofilm assay. The bacteria were grown and the treated with the dendrimers in 96 well plate in a 
similar fashion as incase of MIC study. The 96 well plates were left for incubation at 37OC for 48 
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hours. The plate was shaken over an empty tray to remove all the planktonic bacteria. The 96-well 
plate was then rinsed in a large tray of water and shaken. Rinsing of the plate in water was done a 
couple of times. The plate was hit against the paper towel to get rid of the water from the wells and 
was laid on another paper towel and left to dry overnight. The wells were stained with 125 μL 0.1% 
crystal violet solution for 10 minutes. The plate was shaken over the empty tray to remove the solution 
and the plate was rinsed with water a couple of times until the wells are free of any liquid crystal violet 
and left to dry overnight. 200 μL of 30% acetic acid were added to the wells to solubilize the stained 
crystal violet and left for 10 min. 125 μL of the solution was transferred from each well into a flat-
bottom 96-well plate. The plate was read at OD 595nm with a plate reader.34 The average of the blank 
wells was subtracted from the OD of each sample that contained sample and the average of the wells 
with samples were calculated. The averages of the sample wells were normalized to the average of the 
control wells.4 
3.4 Conclusion 
We have developed a new class of antimicrobial lipidated dendrimer that can mimic the HDPs. 
The amphiphilicity that was required for the dendrimer to display potent and broad-spectrum activity 
against a range of multidrug-resistant Gram-negative and Gram-positive bacteria was identified. These 
lipidated dendrimers were also proven to act as good biofilm inhibitors providing an exciting route to 
develop cost efficient and less tedious drugs against biofilm and drug resistant bacterial species. 
Furthermore, these dendrimers can be used for other biological applications to treat various fungal, 
viral infections and their activity is yet to be explored. 
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CHAPTER 4: SMALL ANTIMICROBIAL AGENTS BASED ON ACYLATED REDUCED 
AMIDE SCAFFOLD 
   
Note to Reader 
Contents in this chapter have been previously published in J. Med. Chem., 2016, 59, 7877 - 
7887 and have been reproduced with the permission from the American Chemical Society (ACS). 
4.1 Introduction 
Antibiotic resistance in bacteria is one of the most critical concerns faced in global public 
health.1 Notorious multidrug-resistant strains, including Gram-positive bacteria methicillin-resistant 
Staphylococcus epidermidis (MRSE), methicillin-resistant Staphylococcus aureus (MRSA), 
Vancomycin-Resistant Enterococci faecalis (VRE), and Gram-negative bacteria Escherichia coli (E. 
Coli), Klebsiella pneumoniae, Pseudomonas aeruginosa, have emerged to be the major cause of 
hospital and community-acquired infections.2, 3 As conventional antibiotics are observed to elicit 
escalating resistance, significant efforts have been extended to the investigation of host-defense 
peptides (HDPs) and their derivatives as alternative therapeutic strategies.4-6 Natural antimicrobial 
peptides, also known as HDPs, have attracted substantial interest in the past decade, and a few of them, 
such as PMX30063 and LTX109, are currently in clinical trials. 4-7 HDPs are produced by living 
organisms as the first line of defense against a wide variety of infections.5 Unlike conventional 
antibiotics which target specific membrane or intracellular components of bacteria, HDPs 
preferentially interact with bacterial membranes and lead to the destruction of membranes eventually. 
The specificity of HDPs toward bacteria cells over mammalian cells lies on the intrinsic difference 
between bacterial and mammalian cell membranes. It is known that the outer leaflet of mammalian 
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cell membranes are comprised of zwitterionic lipids such as cholesterol, phosphatidylcholine, and 
sphingomyelin. Their negatively charged phospholipids are generally sequestered in the inner leaflet 
of membranes.2, 8 In contrast, negatively charged phospholipids including cardiolipin and 
phosphatidylglycerol are frequently identified in the outer leaflet of bacterial membranes.9 In addition, 
negatively charged molecules such as teichoic acids and lipoteichoic acids are membrane components 
of most Gram-positive bacteria, while lipopolysaccharides are characteristic molecules on the outer 
membranes of Gram-negative bacteria. As a result, bacterial membrane surfaces are generally more 
negatively charged than those of mammalian cells, leading to interaction with cationic HDPs 
preferentially. Although detailed antimicrobial mechanism of HDPs are still under debate, a few 
models including barrel stave, carpet, toroidal pores have been proposed, all of which more or less 
possess surfactants-like behavior.2, 10 For instance, lipopeptides have been considered as the most 
potent natural biosurfactants.11 As the interaction is based on physical charge-charge interaction and 
lacks defined membrane targets, it is believed that HDPs may decrease the risk of resistance 
development.12 This is also why HDPs possess broad-spectrum antibacterial activity and they are often 
bactericidal rather than bacteriostatic observed for most conventional antibiotics.2 It should be noted 
that some HDPs do have defined intracellular targets including proteins, nucleic acids and ribosomes, 
however, their cationic amphipathic structure is still crucial for their entry into bacterial cells, and 
membrane disruption may be the additional mechanism of action which further synergizes their 
antimicrobial activity.9  
Nevertheless, HDPs face considerable challenges for further antibiotic development, among 
which low stability, moderate activity and cost for production are major obstacles.13 Oligomeric 
peptidomimetics are resistant to proteolytic degradation, and through optimization, peptidomimetics 
such as  peptoids,14 β-peptides,15-17 oligoureas,18 and AApeptides19-24 can mimic the structure and 
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function of HDPs and show potent and broad-spectrum activity against multidrug-resistant bacterial 
pathogens. Thus, they hold promise for future development of new class of antimicrobial agents. 
However, their structural complexity and large molecular weights (>1500 Da) make the synthetic 
process tedious and time consuming, significantly hindering the translation of HDPs into clinical 
applications. To overcome the drawbacks, considerable endeavors have been devoted to the 
development of small molecular mimetics of HDPs of simplicity. Examples include arylamide 
foldamers,25 small peptoid mimics,26, 27 β-amino acid derivatives,28 dipeptide derivatives,29 and aryl 
compounds.30 In particular, it is exciting to witness that arylamide foldamers PMX series and dipeptide 
derivatives LTX compounds are currently either in Phase II or III clinical trials (Figure 4.1), 
demonstrating the therapeutic potential of small HDP-mimicking antibiotic agents. 
 
Figure 4.1 Structure of PMX-30063 and LTX-109, and design of small antimicrobial agents based on 
the acylated reduced amide. R1 represents cationic groups, R2, R3, and R4 represent hydrophobic 
groups. 
Reduced amide derivatives are peptides containing reduced amide bond, and have been widely 
used as isosteric replacements for peptides (Figure 4.2).31 Even with one amide bond reduced to give 
secondary amine, the peptide sequences display significantly enhanced resistance to enzymatic 
degradation in contrast to canonical peptides.31  Recently there is growing interest in the exploration 
of biological application of reduced-amide-containing compounds, such as the use as enzyme 
inhibitors,32 analogues of endogenous peptides,33 synthetic vaccines,34 and DNA-complexing agents 
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for gene delivery.35 Several reduced-amide-containing sequences were also reported to mimic HDPs 
as they are more resistant to proteolytic degradation.36 Indeed, AApeptides as oligomeric acylated 
reduced-amides were shown to display broad-spectrum antibacterial activity.37, 38 However, these 
reduced-amide-containing oligomers are fairly long and large (MW >1800) sequences, and therefore 
their further optimization and potential for antibiotic therapeutics is still limited. 
 
Figure 4.2 The general chemical structures of α-peptide and reduced amide pseudopeptide. 
4.2 Results and Discussion 
To identify antibiotic agents with potentially more practical applications, herein we report the 
design and development of a class of small antimicrobial molecules containing acylated reduced amide 
(Figure 4.1). They are essentially built on a reduced dipeptide scaffold however with variable side 
chains. We hypothesized that if R1 is a cationic group, while R2, R3 and R4 are hydrophobic, the global 
structure of the molecules should be amphipathic, and thus they are expected to mimic HDPs and kill 
bacterial via membrane disruption. We anticipated that there are advantages associated with the 
molecular design. Reduced amide has been demonstrated for their biological potential and stability. 
The design is also very straightforward and universal, as functional groups can be introduced very 
easily. Moreover, the activity of the molecules could be tuned by varying the hydrophobicity of R2, 
R3 and R4 groups. As such, it is intriguing to investigate the antimicrobial activity of this class of small 
molecules, and to evaluate their potential as antibiotic therapeutics. 
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Figure 4.3 The general scheme for the preparation of small reduced dipeptide derivatives. 
 
The synthesis of these molecules was straightforward (Figure 4.3). Please see supporting 
information for details). Briefly, the building block39 bearing the R2 side chain was attached to chloro-
trityl resin. After Fmoc group was removed, the R3 moiety was attached to the secondary amine. Next, 
the alloc protecting group was removed, followed by capping with the R1 group. The molecule was 
then cleaved from the solid support, to which the R4 functionality was appended to the c-terminus to 
give the final product. We synthesized a series of such small molecules, and the structures of some 
lead compounds are shown in Table 4.1. Their antibacterial activity was also tested against a few 
clinically relevant bacteria, including multi-drug resistant Gram-positive and Gram-negative bacterial 
pathogens (Table 4.1).23, 40   
Table 4.1 The structure of small antimicrobial molecules and their antibacterial activity.  
# Structure  
MIC (µg/mL) Hemolysis  
(HC50, µg/mL) 
IC50 (µg/mL) 
Gram - Gram + 
E. coli P. aeruginosa K. pneumoniae MRSA MRSE VRE HK-2 K562 
1 
 
>50 >50 >50 25-50 25–50 25–50 NTa NT NT 
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2 
 
25–50 6–12 25–50 25–50 25–50 25–50 NT NT NT 
3 
 
>50 >50 >50 >50 >50 >50 NT NT NT 
4 
 
>50 >50 >50 >50 >50 >50 NT NT NT 
5 
 
25 12.5 25 25 12.5 25 290 NCb NC 
6 
 
50 25 25 25 12.5 25 300 >100 >100 
7 
 
12.5 6.12‒12.5 12.5 6.25 6.25 12.5 225 NC NC 
8 
 
6.25 25 12.5 6.25 6.25 6.25 180 NC NC 
9 
 
6.25 12.5 12.5 6.25 6.25 6.25 160 NC NC 
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10 
 
6.25 12.5 6.25 6.25 3.12 6.25 200 NC NC 
11 
 
6.25 6.25 6.25 6.25 3.12 6.25 120 NC NC 
12 
 
3.12 6.25 6.25 3.12 3.12 6.25 210 NC NC 
13 
 
3.12 6.25 6.25 1.56 3.12 6.25 85 
86.3± 
3.0 
83.2± 
4.3 
14 
 
6.25 6.25 >25 1.56 3.12 6.25 280 NC NC 
15 
 
6.25 6.25 >25 3.12 3.12 6.25 200 NC NC 
16 
 
6.25 6.25 >25 3.12 3.12 6.25 250 NC NC 
17 Daptomycin >50 >50 >50 0.5 0.5 1    
18 Colistin 0.5 1 0.5 >50 >50 >50    
a NT, Not tested because compounds are not active. 
b NC, No cytotoxicity toward HK-2 and K562 cells at 25 μg/mL. 
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The microbial organisms used in the study were K. pneumoniae (ATCC 13383), P. aeruginosa 
(ATCC 27853), E. coli (ATCC 25922), Methicillin-resistant S. epidermidis (MRSE) (RP62A), 
Methicillin-resistant S. aureus (MRSA) (ATCC 33591), vancomycin-resistant E. faecalis (ATCC 
700802). The minimum inhibitory concentration (MIC) is the lowest concentration that completely 
inhibits microbial growth after 20 h.24, 37 HC50 is the concentration causing 50% hemolysis. Hemolysis 
activity was not measured for peptidomimetics that did not exhibit antimicrobial activity. 
Daptomycin41 and colistin,42 which are last-resort antibiotics and active against either Gram-positive 
or Gram-negative bacteria, were included for comparison. 
As shown in Table 4.1, with MWs ranging from 600 to 800, many molecules have shown good 
antibacterial activity against a panel of multi-drug-resistant Gram-positive and Gram-negative 
bacteria. The structure-activity relationship is also obvious in this class of molecules allowing for their 
further optimization and development in the future. In compound 1, R1 and R4 are hydrophobic 
naphthyl groups, while R2 and R3 are cationic groups. This compound did not show any antibacterial 
activity at the tested condition, possibly because the structure doesn’t have segregated hydrophobic 
and cationic domains. We next kept R1 as a cationic group, and started to change the hydrophobicity 
of R2, R3 and R4. As seen in compounds 2–4, when R2 is hydrophilic, the compounds were still not 
effective, albeit compound 2 exhibited some activity against all strains. This is likely due to the 
insufficient hydrophobicity of the molecules which do not endow the molecules with membrane 
activity. However, when R2, R3 and R4 groups are all hydrophobic, the compound 5 started to show 
activity against both Gram-positive and Gram-negative bacteria. It suggested that all R2, R3 and R4 
groups have to be hydrophobic so as to possess sufficient interactions with bacterial membranes. We 
also noticed that the guanidino cationic group is slightly weaker than the amino group in eliciting 
antimicrobial activity, thus we focused on the development of derivatives containing cationic amino 
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groups. It was found that the antibacterial activity is highly related to the overall hydrophobicity of 
R2, R3 and R4. Change of R3 to adamantyl group seemed significantly improved the antimicrobial 
activity of 7, as its MIC against MRSE was in the range of 3.12–6.25 µg/mL already. When R4 became 
more hydrophobic, for instance, being two phenyl groups, or biphenyl group, the activity of compound 
8 and 9 was further improved to be 3.12–6.25 µg/mL for most of strains. Substitution on the aromatic 
group on R4 was also likely to boost activity, as seen for 10, 11 and 12, which contain the CF3 or t-
butyl groups on the aromatic ring, displayed further enhanced activity. For instance, both 11 and 12 
had the activity of less than 6.25 µg/mL for all tested strains. It should be noted that these compounds 
are quite selective as their hemolytic activity are all more than 100 µg/mL. We hypothesized that the 
antibacterial activity could be further enhanced by increasing the hydrophobicity of R4, and thus the 
compound 13 was designed. This compound contained adamantyl groups on both R3 and R4 position, 
and as anticipated, it displayed more potent activity against MRSA with MIC of 1.56 μg/mL. It is 
known that hemolytic activity could be mitigated through the introduction of cationic charges.43 We 
next designed the compound 14, which contained one more lysine residue on the R1 position compared 
with 13. As expected, with one more cationic charge, compound 14 exhibited less hemolytic activity. 
However, the antibacterial activity of compound 14 was also less than 13. Similar results were 
observed for 15 and 16 as well, suggesting that more lysine residues may not be preferred for bacterial 
killing. It is also interesting that with the replacement of lysine residue in 14 by an ornithine residue, 
compound 15 shows slightly increased hemolytic activity, even though the overall cationic charges 
remain the same. It maybe because the side chain of lysine is slightly longer than that of ornithine, 
which decreases the potential non-specific interactions. In addition, replacement of the lysine residue 
with arginine residue didn’t impact significantly either on antibacterial activity or on hemolytic 
activity, as seen for 14 and 16, both of which show comparable selectivity towards bacteria. Next, we 
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also tested the cytotoxicity of these compounds against HK-2 and K562 cells. Interestingly, although 
amphipathic agents are often cytotoxic, our compounds did not show noticeable cytotoxicity at the 
concentration of 25 μg/mL against both HK-2 and K562 cells. The lead compound 13 has EC50 of 86.3 
and 83.2 μg/mL against HK-2 and K562 cells, respectively, >50 fold of selectivity for MRSA. 
As these acylated reduced-amide molecules were designed to possess global amphipathic structure of 
HDPs, we hypothesized they could mimic the mechanism of action of HDPs and exert their 
bactericidal activity by disrupting bacterial membranes. To evaluate the ability of these compounds to 
compromise bacterial membranes, fluorescence microscopy was used to visualize the impact of 
compounds on membranes of S. aureus.19 Although 11–13 have similar activity against the tested 
panel of bacteria, 13 and 14 were chosen in the study as they show most potent activity in killing 
MRSA. Two dyes, 4',6-diamidino-2-phenylindole (DAPI), and propidium iodide (PI) (Figure 4.4), 
were employed in the study. It is known that DAPI could stain membranes of bacterial cells with blue 
fluorescence irrespective of cell viability, however, the red fluorescence of PI due to the DNA 
intercalation could only be observed in the presence of impaired membranes that are permeable to PI. 
As shown in Figure 4.4, in the DAPI channel (460 nm), S. aureus in the control groups are visible. 
However, they are not visible under the PI channel (620 nm). After bacteria were incubated with either 
13 or 14, they fluoresce under both PI and DAPI channels, suggesting the membranes of S. aureus 
were damaged.  
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Figure 4.4 Fluorescence micrographs of S. aureus that are treated or not treated with 25 µg/mL of 13 
or 14 for 2 h. a1, control, no treatment, DAPI stained; a2, control, no treatment, PI stained. b1, 
treatment with 13, DAPI stained; b2, treatment with 13, PI stained. c1, treatment with 14, DAPI 
stained; c2, treatment with 14, PI stained. Scale bar = 10 µm. 
It is known that membrane-active antibiotic agents could exert their bactericidal activity very 
rapidly, a phenomena that has been widely observed in HDPs.44 We thus next conducted time-kill 
study to investigate if 13 and 14 could rapidly kill MRSA in a dose-dependent fashion. Cell colonies 
were counted in agar plates at different time points at 4-, 8-, 16-fold of the MIC. As shown in Figure 
4.5, the compounds 13 and 14 at the concentration of either 25 or 50 µg/mL could remove all bacteria 
completely in just two hours. This observation indicates that 13 and 14 act in a similar manner to that 
of HDPs.   
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Figure 4.5 Time-kill curves of 13 (a) and 14 (b) for MRSA. The killing activity was monitored for the 
first 2 h. The concentrations were 4 ×MIC, 8 ×MIC, and 16 ×MIC, respectively. 
It is known that HDPs do not induce resistance in bacteria readily because they disintegrate 
bacterial membranes, 45 a mechanism lacking of defined molecular targets. To evaluate the probability 
of these reduced-amide based small molecules to elicit resistance in bacteria, we carried out the drug 
resistance studies of 13 and 14 against MRSA. Their MICs towards MRSA were first measured, and 
then these compounds were incubated with bacteria in the well of the half-MIC, and tested for their 
activity again.  As shown in Figure 4.6, after 14 passages, MICs of both 13 and 14 are virtually very 
constant, indicating that these compounds do not induce drug-resistance in MRSA, which suggests 
their mode of action is analogues to that of HDPs.  
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Figure 4.6 Drug-resistance study of 13 and 14 toward MRSA. 
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The biofilm is a notorious problem because bacteria in biofilm are generally more difficult to 
eradicate than planktonic cells. Thus, it could lead to severe chronic infectious diseases which 
complicate the treatment. In addition, the biofilm is also known to contaminate medical devices 
contributing to hospital acquired infections.46 The biofilm formed by Gram-negative bacteria are even 
more challenging due to their stronger resistance. It is known than biofilms of E. coli and A. 
baumannii have posted great threat to community, and thus compounds which prevent their biofilm 
formation could lead to novel therapeutics. 47, 48 To evaluate the potential of the reduced-amide derived 
molecules in the biofilm prevention, the compound 13 was evaluated for its ability to inhibit the 
biofilm formation of E. coli and A. baumannii. As shown in Figure 4.7, at just a concentration of 0.6 
µg/mL, 13 could inhibit more than 50% of biofilm formation of both E. coli and A. baumannii. At the 
concentration of 2 µg/mL, it almost completely eradicated their biofilms.   
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Figure 4.7 Biological activity of compound 13 on inhibition of biofilm by A. baumannii and E. coli. 
Pneumonia is one of the most severe diseases caused by bacterial infection.49 Community-acquired 
MRSA induced pneumonia has led to significant medicare cost and modality. Encouraged by the in 
vitro anti-bacterial profiles of our compounds, we tested their efficacy on a rat model bearing MRSA-
induced ventilator-associated pneumonia,50 in order to evaluate their therapeutic potential. In this 
model anti-inflammatory activity is used as a surrogate for clearing the infection. The pathological 
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analysis (Figure 4.8a) show that local nasal administration of MRSA infection stimulated acute 
inflammation response in lungs, as indicated by the prevalence of neutrophils (blue spots in H&E 
staining). In the control group which was treated with saline, typical inflammation caused by 
pneumonia persisted over three days. In contrast, significant reduction of lung infiltrated pro-
inflammatory cells could be observed post i.v. administration of compound 13 (10 mg/kg), strongly 
support the effectiveness of our antibacterial agents. To further support the observation, the level of 
the inflammatory cytokine TNF-α was also quantified by the ELISA assay. As shown in Figure 4.8b, 
the level of TNF-α cytokine increased over time in bronchoalveolar lavage fluid from the control rat 
group received saline only, suggesting the persistence of lung inflammation. However, with the 
treatment of 13, the cytokine level was lowered down even after 1 day. After 3 days post treatment, 
the level of TNF-α level decreased, which was almost half of the level in control. The in vivo studies 
suggest that the compound 13 is capably of effectively suppressing the acute lung inflammation caused 
by pneumonia.  
Figure 4.8 In vivo efficacy of the compound 13 on a MRSA-induced ventilator-associated 
pneumonia bearing rat model. a, pathological assay via H&E staining; b, TNF-α cytokine level in 
the rats by ELISA assay. 
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4.3 Conclusion 
To summarize, we have developed a series of small antimicrobial agents based on the acylated 
reduced amide scaffold. These molecules display good potency against a panel of multidrug-resistant 
Gram-positive and Gram-negative bacteria. Although other antimicrobial mechanisms cannot be 
excluded, our mechanistic studies suggest that these compounds could kill bacteria rapidly by 
disrupting bacterial membranes, a mechanism analogous to that of host-defense peptides (HDPs). The 
hypothesis is further supported by the fact that the susceptibility of MRSA bacteria to the lead 
compounds remains nearly unchanged even after 14 passages. Meanwhile, they also exhibit high 
potency to inhibit the formation of biofilms. Furthermore, anti-inflammatory potential of these 
molecules was confirmed in the MRSA-induced pneumonia-bearing rat model. Although these types 
of agents have moderate to good selectivity so far, our work shed light on the development of more 
potent compounds. Compared to HDPs, facile synthesis and high cost-effectiveness of these 
compounds make them appealing classes of antibiotic agents combating drug-resistant bacterial 
strains. Further studies on optimization of activity and selectivity, as well pharmacokinetic analysis is 
underway in our lab. 
4.4 Experimental section 
General information.  All Fmoc protected α-amino acids and Rink-amide resin (0.7 mmol/g, 200-
400 mesh) were purchased from Chem-Impex International, Inc. Solvents and other reagents were 
purchased from either Sigma-Aldrich or Fisher Scientific and were used without further purification. 
Solid-phase synthesis of the compounds was carried out in the peptide synthesis vessel on a Burrell 
Wrist-Action shaker. The products were purified on a Waters Breeze 2 HPLC system, and lyophilized 
on a Labconco lyophilizer. The purity of the compounds was determined to be >95% by analytical 
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HPLC (1 mL/min flow, 5% to 100% linear gradient of solvent B (0.1% TFA in acetonitrile) in A (0.1% 
TFA in water) over 40 min was used). The NMR spectra were obtained on a Varian Inova 400 
instrument. 
 
Synthesis of desired compounds. Synthesis of 7 is shown below.  
 
Figure 4.9 Typical synthetic route for compound 7 
The other compounds were synthesized following the similar procedure of 7. 2-Chlorotrityl 
chloride (CTC) resin (200 mg, 0.2 mmol) was swelled in 3 mL DCM for 15 min. The attachment of 
the first building block to the resin was achieved by adding γ-BB-1 (154 mg, 0.3 mmol) and N,N-
diisopropylethylamine (DIPEA) (173 μL, 1 mmol) to the beads in the reaction vessel, which was 
allowed to shake at room temperature for 2 h. After that, the reaction solution was drained, followed 
by washing with DMF (2 mL×3) and DCM (2 mL×3). The unreacted 2-chlorotrityl chloride moieties 
were capped with 3 mL methanol for 30 min. The beads were washed with DCM (3 mL×3) and DMF 
(3 mL×3). The Fmoc group was removed by treating beads with 20% piperidine/DMF (v/v) solution 
for 10 min (×2) at room temperature. The solution was drained and washed with DMF (3 mL×3) and 
DCM (3 mL×3). The beads were reacted with 1-admantaneacetyl chloride (72 μL, 0.4 mmol) and 
DIPEA (87 μL, 0.5 mmol) for 30 min (×2) at room temperature, and the solution was removed. After 
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DMF (2 mL×3) and DCM (2 mL×3) wash, the beads were treated with Pd(PPh3)4 (24 mg, 0.02 mmol) 
and Me2NH.BH3 (70 mg, 1.2 mmol) in 2 mL DCM for 10 min (×2) to remove the alloc protecting 
group. After the reaction, the solution was drained, and the beads were washed with DCM (3 mL×3) 
and DMF (3 mL×3). Next, Fmoc-Lys(Boc)-OH (187 mg, 0.4 mmol), N,N-diisopropylcarbodiimide 
(DIC) (84 μL, 0.8 mmol), and hydroxybenzotriazole (HOBt) (122 mg, 0.8 mmol) were pre-mixed in 
2 mL DMF for 5 min before getting transferred to the reaction vessel. The reaction was shaken at room 
temperature for 3 hours, and the solution was drained. Then the intermediate was cleaved from resin 
with 5 mL of the cleavage cocktail (acetic acid:2,2,2-trifluoroethanol: DCM 1:1:8, v/v/v) for 2 h, the 
solution was collected and the remaining beads were washed with 3 mL of the cleavage cocktail 
solution for three times. All the solution was combined and concentrated in vacuo with co-evaporation 
with hexane multiple times to completely remove acetic acid. A white solid intermediate was obtained. 
This intermediate was pre-mixed with HOBt and DIC in DMF for 5 min, followed by the addition of 
1-Naphthylmethylamine. The clear faint yellow solution was stirred at room temperature for 5 h, then 
water was added to quench the reaction, followed by ethyl acetate (EtOAc) extraction. The organic 
layer was washed with 1M HCl (×3) then brine (×1), dried over anhydrous Na2SO4 and concentrated 
by vacuum. The residue was treated with 50% TFA in DCM for 2 h and then the solvent was removed 
with the N2 flow. The residue was then treated with 50% diethylamine in CH3CN for 30 min to remove 
Fmoc protecting group, followed by the removal of the solvent. The crude was analyzed and prepared 
on Waters HPLC system, followed by lyophilization to give the pure product 7. 
Compound 1. 1HNMR (400 MHz, d6-DMSO) δ 8.26–8.65 (m, 2H), 7.80–8.03 (m, 5H), 7.54–7.79 (m, 
6H), 7.37–7.53 (m, 3H), 4.60–4.74 (m, 1.5H), 4.23–4.28 (m, 0.8H), 3.85–4.13 (m, 2H), 3.48–3.66 (brd 
m, overlapped with H2O, 4.5H), 3.41 (dd, J = 14.8, 9.2 Hz, 0.6H), 3.26 (dd, J = 14.8, 9.2 Hz, 0.5H), 
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2.61–2.75 (m, 3H), 2.50–2.59 (m, 1H), 2.12–2.80 (m, 0.8H), 1.26–1.75 (m, 6H). HRMS (ESI) 
C34H42N5O3 [M+H]
+ calc’d = 568.3282; found = 568.3271. 
Compound 2. 1HNMR (400 MHz, d6-DMSO) δ 8.99 (t, J = 5.6 Hz, 0.3H), 8.47–8.52 (m, 1H), 8.10 
(brd, 2H), 7.93 (d, J = 8.0 Hz, 2H), 7.90 (s, 1H), 7.81 (t, J = 7.2 Hz, 2H), 7.77 (brd, 1H), 7.69 (d, J = 
8.0 Hz, 1.3H), 7.42–7.59 (m, 5H), 7.28 (t, J = 7.2 Hz, 0.8H), 7.15 (d, J = 6.4 Hz, 0.7H), 4.71–4.83 (m, 
0.8H), 4.68 (brd, 1.4H), 4.00–4.39 (m, 2.6H), 3.69 (overlapped, 2H), 2.74–2.83 (m, 2H), 1.21–1.60 
(m, 6H). HRMS (ESI) C30H35N4O2 [M+H]
+ calc’d = 483.2755; found = 483.2756. 
Compound 3. 1HNMR (400 MHz, d6-DMSO) δ 8.59 (t, J = 5.6 Hz, 0.4H), 8.36–8.41 (m, 1H), 8.22 
(d, J = 8.8 Hz, 0.6H), 8.14 (brd, 2H), 8.03 (dd, J = 6.4, 2.4 H, 1H), 7.93 (td, J = 5.6, 1.8 Hz, 1H), 7.80–
7.86 (m, 1.8H), 7.6 (brd, 4H), 7.39–7.54 (m, 3.5H), 4.73 (dd, J = 12.8, 5.6 Hz, 1.8H), 4.12 (d, J = 15.2 
Hz, 0.5H), 3.93–4.08 (m, 2H), 3.63–3.72 (m, 3H), 3.32 (dd, J = 15.2, 4.8 Hz, 1H), 3.08 (dd, J = 13.6, 
8.0 Hz, 0.6H), 2.70–2.73 (m, 3H), 2.40 (d, J = 13.6 Hz, 1H), 1.72–1.93 (m, 4H), 1.47–1.63 (m, 18H), 
1.13–1.35 (m, 5H). HRMS (ESI) C37H57N6O3 [M+H]+ calc’d = 633.4487; found = 633.4485. 
Compound 4. 1HNMR (400 MHz, d6-DMSO) δ 8.34–8.64 (m, 2H), 8.19 (brs, 2.8H), 7.90–7.99 (m, 
3.5H), 7.70–7.81 (m, 8H), 7.41–7.58 (m, 4H), 7.26–7.32 (m, 1H), 7.16 (d, J = 6.8 Hz, 0.6H), 4.78 
(brd, 0.5H), 4.63 (d, J = 5.2 Hz, 1.3H), 4.10–4.25 (m, 1.4H), 3.96 (brd, 2H), 3.17 (overlapped, 2H), 
3.46–4.39 (m, 2H), 3.24–3.30 (m, 0.6H), 2.56–2.74 (m, 4.4H), 1.51–1.74 (m, 5H), 1.20–1.42 (m, 6H), 
1.00–1.14 (m, 1H). HRMS (ESI) C36H46N6NaO3 [M+Na]+ calc’d = 633.3524; found = 633.3636. 
Compound 5. 1HNMR (400 MHz, d6-DMSO) δ 8.66 (t, J = 4.4 Hz, 0.3), 8.44–8.66 (m, 1.5H), 8.16 
(brd, 2H), 7.96 (t, J = 8.0 Hz, 3H), 7.85 (t, J = 8.0 Hz, 2H), 7.76 (brd, 2H), 7.43–7.63 (m, 4.8H), 7.18–
7.36 (m, 5H), 6.86–7.09 (m, 1H), 4.47–4.83 (m, 3.8H), 4.12–4.16 (m, 2.8H), 3.96–4.06 (m, 1.6H), 
3.06–3.76 (m, 2.5H), 2.78–2.92 (m, 1.5H), 2.56–2.67 (m, 1.7H), 1.31–1.78 (m, 6H). HRMS (ESI) 
C39H44N5O3 [M+H]
+ calc’d = 630.3439; found = 630.3424. 
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Compound 6. 1HNMR (400 MHz, d6-DMSO) δ 8.37–8.62 (m, 1.6H), 8.10–8.21 (m, 3H), 7.90–7.97 
(m, 3H), 7.80–7.84 (m, 1.6H), 7.66–7.73 (m, 1H), 7.37–7.58 (m, 5H), 7.15–7.32 (m, 6.6H), 6.83–7.01 
(m, 1.7H), 4.80–4.92 (m, 0.5H), 4.63–4.68 (m, 1H), 4.39–4.46 (m, 1H), 4.12–4.30 (m, 2H), 3.99 (d, J 
= 17.2 Hz, 2H), 3.82 (dd, J = 13.6, 6.4 Hz, 0.6H), 3.65–3.69 (m, 1H), 3.39–3.55 (m, 1H), 2.78–3.07 
(m, 2H), 2.51–3.07 (m, 0,6H), 0.87–1.73 (m, 4H). HRMS (ESI) C39H44N7O3 [M+H]+ calc’d = 
658.3500; found = 658.3496. 
Compound 7. 1HNMR (400 MHz, d6-DMSO) δ 8.57–8.63 (m, 1H), 8.32–8.34 (m, 1H), 8.01–8.09 (m, 
3H), 7.92 (dd, J = 9.6, 6.0 Hz, 1H), 7.78–1.85 (m, 3H), 7.40–7.53 (m, 4H), 7.14–7.30 (m, 4H), 4.68–
4.77 (m, 2H), 4.07–4.21 (m, 2H), 3.83–4.02 (m, 4.8H), 3.66–3.69 (m, 0.9H), 3.47–3.58 (m, 1.2H), 
3.37–3.48 (m, 1H), 3.15 (dd, J = 13.6, 7.6 Hz, 0.5H), 2.65–3.91 (m, 3.4H), 2.04–2.15 (m, 0.5H), 1.74–
1.92 (m, 4H), 1.45–1.63 (m, 14H), 1.19–1.36 (m, 2.8H). HRMS (ESI) C40H54N5O3 [M+H]+ calc’d = 
652.4221; found = 652.4204. 
Compound 8. 1HNMR (400 MHz, d6-DMSO) δ 8.57 (d, J = 8.8 Hz, 0.5H), 8.31 (d, J = 8.8 Hz, 0.5H), 
8.05 (brd, 2H), 7.77 (brd, 2H), 7.15–7.38 (m, 16H), 4.61–4.67 (m, 0.5H), 4.25–4.57 (m, 5H), 4.13–
4.18 (m, 1H), 4.00–4.08 (m, 1H),3.47–3.64 (m, 4H), 3.12 (dd, J = 9.6, 7.2 Hz, 0.6H), 2.62–2.78 (m, 
4H), 2.25 (d, J = 13.6 Hz, 0.6H), 1.76–1.86 (m, 3H), 1.52–1.72 (m, 10H), 1.38–1.47 (m, 3H), 1.11–
1.35 (m, 6H). HRMS (ESI) C43H58N5O3 [M+H]
+ calc’d = 692.4534; found = 692.4517. 
Compound 9. 1HNMR (400 MHz, d6-DMSO) δ 8.51–8.61 (m, 0.8H), 8.29–8.33 (m, 1H), 8.01–8.09 
(m, 2.3H), 7.75 (brd, 2H), 7.54–7.61 (m, 3H), 7.42 (t, J = 7.2 Hz, 2H), 7.14–7.34 (m, 7H), 4.09–4.31 
(m, 3H), 3.83–4.03 (m, 2H), 3.67 (m, 2H), 3.36–3.44 (m, 2H), 2.17 (dd, J = 13.6, 8.0 Hz, 0.6H), 2.51–
2.78 (m, 4H), 1.76–2.13 (m, 4H), 1.43–1.61 (m, 15H), 1.18–1.19 (m, 2H). HRMS (ESI) C42H56N5O3 
[M+H]+ calc’d = 678.4378; found = 678.4365. 
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Compound 10. 1HNMR (400 MHz, d6-DMSO) δ 8.52–8.70 (m, 1H), 8.31–8.42 (m, 1H), 8.05–8.09 
(brdm, 2H), 7.75 (m, 2H), 7.72 (dd, J = 20.0, 8.0 Hz, 2H), 7.43–7.48 (m, 2H), 7.12–7,30 (m, 5H), 
4,31–4,32 (m, 2H), 4.09–4.21 (m, 1H), 3.81–4.03 (m, 2H), 3.66–3.68 M, 1H), 3.36–3.43 (m, 2H), 3.14 
(dd, J = 13.6, 8.0 Hz, 0.5H), 2.51–2.78 (m, 4H), 2.11 (J = 13.6 Hz, 0.5H), 1.75–1.93 (m, 4H), 1.47–
1.56 (brdm, 15H), 1.12–1.29 (m, 2H). HRMS (ESI) C37H51F3N5O3 [M+H]+ calc’d = 670.3939; found 
= 670.3930. 
Compound 11. 1HNMR (400 MHz, d6-DMSO) δ 8.43–8.57 (m, 1H), 8.31 (d, J = 12.4 Hz, 0.4H), 8.21 
(t, J = 5.6 Hz, 0.6H), 7.99–8.09 (brdm, 2.7H), 7.76 (brd, 2H), 7.12–7.35 (m, 8H), 4.14–4.22 (m, 3H), 
3.80–4.05 (m, 3H), 3.65 (m, 1H), 3.35–3.53 (m, 3H), 3.16 (dd, J = 13.6, 8.0 Hz, 0.5H), 2.51–2.91 (m, 
4H), 2.10 (d, J = 13.6 Hz, 0.6H), 1.72–1.94 (m, 4H), 1.50–1.58 (brdm, 14H), 1.07–1.37 (m, 12H). 
HRMS (ESI) C40H60N5O3 [M+H]
+ calc’d = 658.4691; found = 658.4680. 
Compound 12. 1HNMR (400 MHz, d6-DMSO) δ 8.77 (dd, J = 12.0, 6.0 Hz, 0.4H), 8.54 (d, J = 8.8 
Hz, 0.4H), 8.47 (t, J = 6.0 Hz, 0.6H), 8.31 (d, J = 8.4 Hz, 0.4H),  8.04–8.08 (brdm, 2.7H), 7.97 (s, 
0.6H), 7.93 (brs, 2H), 7.75 (brd, 2H), 7.14–7.29 (m, 4.6H), 4.41–4.46 (m, 2H), 4.15–4.20 (m, 1H),  
3.81–4.10 (m, 3H), 3.59 (m, 1H), 3.35–3.53 (m, 2.6H), 3.13 (dd, J = 13.6, 8.0 Hz, 0.4H), 2.51–2.85 
(m, 4H), 2.08 (d, J = 13.6 Hz, 0.5H), 1.63–1.87 (m, 5H), 1.49–1.58 (brdm, 14H), 1.20–1.31 (m, 2H). 
HRMS (ESI) C38H50F6N5O3 [M+H]
+ calc’d = 738.3812; found = 738.3815. 
Compound 13. 1HNMR (400 MHz, d6-DMSO) δ 8.57 (t, J = 8.4 Hz, 0.4H), 8.34 (t, J = 8.4 Hz, 0.5H), 
8.08 (brd, 2H), 7.89–7.94 (m, 0.6H), 7.78 (brd, 2H), 7.55–7.61 (m, 0.4), 7.18–7.27 (m, 4H), 4.12–4.22 
(m, 1H), 3.93–4.00 (m, 1.3H), 3.62–3.78 (m, 3.6H), 3.15–3.22 (m, 0.7H), 2.73 (brd, 5.3H), 2.42–2.55 
(m, 2.2H), 2.13–2.18 (m, 0.3 H), 1.75–1.92 (m, 7H), 1.52–1.60 (brd, 20H), 1.40 (brd, 7H), 1.20–1.27 
(m, 2H). HRMS (ESI) C40H62N5O3 [M+H]
+ calc’d = 660.4847; found = 660.4855. 
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Compound 14. 1HNMR (400 MHz, d6-DMSO) δ 8.38–8.48 (m, 1H), 8.14 (brd, 2H), 7.88–7.99 (m, 
1.4H), 7.82 (brd, 3H), 7.51–7.57 (m, 0.4H), 7.11–7.25 (m, 4.6H), 3.95–3.18 (m, 3H), 3.67–3.76 (m, 
1.5H), 3.51–3.52 (m, 2H), 3.33–3.37 (m, 2H), 3.02–3.12 (m, 0.5H), 2.51–2.84 (m, 8H), 2.20 (dd, J = 
13.6, 8.0 Hz, 0.4H), 1.79–1.97 (m, 7H), 1.44–1.64 (brdm, 23H), 1.20–1.40 (m, 11H), 0.94 (dd, J = 
14.8, 7.2 Hz, 1H). HRMS (ESI) C46H74N7O4 [M+H]
+ calc’d = 788.5797; found = 788.5797.  
Compound 15. 1HNMR (400 MHz, d6-DMSO) δ 8.50–8.66 (m, 1H), 8.20 (brd, 2H), 7.95–8.18 (m, 
1.8H), 7.80–7.88 (brd, 3H), 7.51–7.62 (m, 0.5H), 7.11–7.27 (m, 4.7H), 3.90–4.18 (m, 7H), 3.52–3.82 
(m, 2.6H), 3.37–3.41 (m, 1H), 2.96–3.96 (m, 0.4H), 2.52–2.87 (m, 8H), 1.78–2.18 (m, 8H), 1.30–1.69 
(brdm, 31H), 0.80–0.93 (m, 1H). HRMS (ESI) C45H72N7O4 [M+H]+ calc’d = 774.5640; found = 
774.5651. 
Compound 16. 1HNMR (400 MHz, d6-DMSO) δ 8.43–8.51 (m, 1H), 8.15–8.21 (m, 0.8H), 8.10 (brd, 
2H), 7.86–8.02 (m, 1.2H), 7.73 (brd, 2H), 7.48–7.63 (m, 1.2H), 7.14–7.24 (m, 5H), 3.90–4.23 (m, 
3.5H), 3.72–3.76 (m, 1.5H), 3.50–3.55 (m, 3H), 2.87–3.15 (m, 3H), 2.57–2.79 (m, 6H), 1.82–1.95 (m, 
7H), 1.10–1.59 (m, 33H). HRMS (ESI) C46H74N9O4 [M+H]+ calc’d = 816.5858; found = 816.5866. 
 
Minimum inhibitory concentrations (MICs) against bacteria. The antimicrobial activity of the 
compounds was tested on the following six bacteria strains: K. pneumoniae (ATCC 13383), P. 
aeruginosa (ATCC27853), E. coli (ATCC 25922), vancomycin-resistant Enterococcus faecalis 
(ATCC 700802), Methicillin-resistant S. aureus (MRSA, ATCC 33591), Methicillin-resistant S. 
epidermidis (MRSE, RP62A). The procedures were followed as reported previously.19 The MICs were 
determined as the lowest concentration that completely inhibits the bacteria growth. The experiments 
were repeated at least three times with duplicates each time.  
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Hemolytic assays. The freshly drawn, K2EDTA treated human red blood cells (hRBCs) were washed 
with 1× PBS buffer, and centrifuged at 3500 rpm for 10 min. The step was repeated until the 
supernatant became clear. The supernatant was removed, and the RBCs were diluted into 5% v/v 
suspension. 50 µL of the suspension was incubated with 50 µL of compounds of different 
concentrations at 37 °C for 1 h. The mixture was centrifuged at 3500 rpm for 10 min. Subsequently, 
to 30 µL of the supernatant 100 µL PBS was added, and the absorbance of the mixture at 540 nm was 
read on a Biotek Synergy HT plate reader. The positive control was 2% Triton X-100, and the negative 
control was 1× PBS alone. The hemolysis activity was calculated by the formula % hemolysis = 
(Abssample-AbsPBS)/(AbsTriton-AbsPBS)×100%. The experiment was repeated at least three times with 
duplicates each time. 
MTT assays. Both HK-2 and K562 cells were used to access the cell viability with treatment of 
compound 5‒16 using standard procedure.22 Cells were seeded in 96-well plate with 5×104 cells in 
100 μL media per well. Control and Blank wells were prepared accordingly. Serial dilutions of 
compounds at concentrations of 100, 50, 25, 12.5, 6.25 μg/mL were prepared by diluting stock solution 
with media. After incubation for 12 h, 100 μL aliquots of drugs were added and the plate was incubated 
for 24 h. All media in cells was then removed and washed with fresh media once, followed by addition 
of 110 μL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent and then 
incubation for another 4 h, after which 100 μL of pre-warmed solubilization solution was added. The 
plate was then incubated at 37 °C for 12 h before absorbance was read at 550 nm. The data was 
calculated based on the following equation: cell viability % = [ (A − Ablank)/ (Acontrol − Ablank)] × 100%. 
The measurements were repeated at least three times. 
Fluorescence microscopy. The fluorescence microscopy was used to assess the ability of the 
compounds to compromise bacterial membranes. Fluorescent dyes propidium iodide (PI) and 4’, 6’-
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diamidino-2-phenylindole dihydrochloride (DAPI) were used in the study. DAPI stains bacteria cells 
irrespective of their viabilities, whereas PI can only permeate bacterial cells and intercalate DNA in 
order to fluoresce when bacterial cell membranes are damaged membranes. After MRSA grew to mid-
logarithmic phase, the compounds 13 or 14 was incubated with the bacteria at 37 °C for 2 h. The 
mixture was then centrifuged at 5000 rpm for 15 min. The cell pellets were washed with the PBS 
buffer for three times, and incubated with PI (5 µg/mL) and DAPI (10 µg/mL) for 15 min sequentially 
on ice in the dark. The mixture was then centrifuged and the pellets were washed with the PBS buffer. 
Next, 10 µL of the samples were placed on chamber slides and observed under Zeiss Axio Image 
Zloptical microscope using 100× oil-immersion objective. 
Time kill study. The kinetics of bacteria killing by the lead compounds 13 and 14 were investigated. 
Briefly, the bacteria MRSA grew to mid-logarithmic phase in tryptic soy broth (TSB) medium, from 
which the suspension (106 colony-forming unit per milliliter (CFU/ml)) were made. The suspension 
was incubated with different concentrations of 13 or 14 for 10 min, 30 min, 1 h and 2 h respectively. 
The mixtures were diluted by 102 to 104 fold and spread on TSB agar plates. After incubation at 37 °C 
overnight, the colonies on the plates were counted and plotted against the incubation time. 
Drug resistance study. The initial MICs of the compounds 13 and 14 for MRSA were obtained as 
above. Bacteria in wells containing concentration of 1/2 MIC were used to make bacterial suspension 
(106 CFU/ml) for the next measurement of MICs of 13 and 14. The experiment was repeated each day 
for 14 passages. 
Inhibition of biofilms. Overnight grown bacteria were inoculated into fresh 10% of MHII broth at a 
ratio of 1:100. 100 µL of inoculated culture was incubated with appropriated amount of compound 13 
in wells of 96-well plate. The plate was incubated at 37 °C for overnight. Optical density of each wells 
was recorded at the wavelength of 600 nm and then the biofilm biomass was recorded by the crystal 
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violet method. Biofilm biomass were presented as CV OD/ OD of growth. Relative biofilm biomass 
values were normalized by the biomass value of control (no addition of compound). Experiments were 
conducted in triplicate and the data were presented as mean ± STDEV. 
 
In vivo study 
Establishment of the rat model of MRSA-induced pneumonia. All animal experiments were 
approved by the institutional committee for animal care of Nanjing University and carried out in 
accordance to the policy of the National Ministry of Health of China. Briefly, male Wistar rats (6‒8 
weeks, average weight 200 g) were subjected to fast for at least 12 h prior to treatment. Then they 
were anesthetized with 1 g/kg of urethane administered intraperitoneally. An endotracheal tube with 
the 16-gage needle front was inserted into the trachea. After the placement of catheter, stethoscope 
was used to confirm the catheter was right in the trachea. Next, 100 μL PBS containing 2×105 
CFU/mL MRSA was injected slowly to induce pneumonia. During the procedure, the rats were 
ventilated with a constant-volume respirator, and parameters were set as the following: inspired O2 
fraction of 1.0; peak airway pressures of 8‒12 cm H2O and a 2-cm positive end expiratory pressure 
(PEEP); as high as 12 mL/kg tidal volume were given every 30 min to avoid potential positional 
pulmonary atelectasis; breathing frequency was controlled at 70 times/min. The respiratory rate was 
adjusted to maintain the pressure of CO2 between 35 and 45 mmHg.  
Pathological analysis. A dose of 10 mg/kg weight of the compound 13 was injected to the tail veins 
of tested rats intravenously. Time course profiles of histological changes in lungs of rats were assessed 
post intravenous injection followed by dissection after being euthanized. Sections from lungs were 
stained with hematoxylin and eosin (H&E) and observed under a light microscope. For pathological 
investigation of lungs of pneumonia suffering rats at different time points, sections were collected as 
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above mentioned and existence (indicated by the infiltration of neutrophils) and the extent of possible 
inflammatory response (indicated by the integrity of the alveolar structure and endothelium cilium) 
were recorded from five randomly picked sections. 
Bronchoalveolar lavage (BAL) assay. The assay was conducted to estimate the situation of 
inflammatory reactions in lungs. Rats were sacrificed and exsanguinated via the femoral vessel under 
sterile condition. Then the thorax was opened, and the 18-gage needle was introduced to the trachea 
at the cricothyroid membrane. Subsequently, 1 mL of sterilized PBS was administrated and extracted 
out for six cycles to promote the elution of inflammatory cells. Upon treatment, each specimen was 
homogenized. The suspension was subjected to enzyme linked immunosorbent assay (Elisa, R&D), 
and the level of Tumor Necrosis Factor-α (TNF-α) cytokine was investigated. 
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CHAPTER 5: NOVEL BIS-CYCLIC GUANIDINES AS POTENT MEMBRANE-ACTIVE 
ANTIBACTERIAL AGENTS WITH THERAPEUTIC POTENTIAL 
Note to Reader 
Contents in this chapter have been previously published in Chem. Commun., 2017 and have 
been reproduced with the permission from the Royal Society of Chemistry. 
5.1 Introduction 
  Antimicrobial resistance is an escalating threat in global public health,1-3 and requires 
consistent actions worldwide. Indeed, multidrug-resistant bacterial strains, include Gram-positive 
bacteria methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus 
epidermidis (MRSE), Vancomycin-Resistant Enterococci (VRE), and Gram-negative bacteria 
Escherichia coli (E. Coli), Klebsiella pneumoniae (KP), and  Pseudomonas aeruginosa (PA), have 
emerged to be the major cause of hospital and community-acquired infections.4, 5 As such, novel 
antibiotics that inhibit a panel of multidrug-resistant bacteria is in an urgent need.6-8   
In recent decade, host-defense peptides (HDPs) have emerged as an alternative approach to combat 
bacteria resistance.9-11 Conventional antibiotics are known to target specific membrane or intracellular 
components of bacteria, however, HDPs preferentially interact with negatively charged bacterial 
membranes due to the intrinsic difference between bacterial and mammalian cell membranes,4, 12, 13 
leading to the destruction of membrane integrity and bacterial cell death. The antimicrobial 
mechanisms of HDPs are complex, and a few models including barrel stave, carpet, toroidal pores 
have been proposed.4, 14 Nonetheless, all potential membrane-disrupting mechanisms could reduce the 
risk of resistance development15 as these interactions with bacteria are based on physical charge-
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charge interaction and lack defined membrane targets. Such mechanisms also confer HDPs with 
broad-spectrum bactericidal activity.4, 16 It should be noted that some HDPs do have defined 
intracellular targets besides their membrane- disruptive activity, nonetheless, these combined 
mechanisms of actions could indeed further synergize their antimicrobial activity.13 Despite 
enthusiasm, there are obstacles associated with antibiotic HDPs and HDP-mimicking oligomeric 
peptidomimetics,17-19 including difficulty in scale-up, low cost-effectiveness, potential 
immunogenicity and systematic toxicity. Therefore, recently there has been considerable interest in 
the search of small molecules which mimic mechanism of action of HDPs.16, 20-22 
  Bis-guanidine related compounds such as hexamidine have been used as antiseptics and 
disinfectant in past decades.23, 24 Recently it is suggested that cyclic guanidine compounds may be 
more potent antibacterial agents than linear guanidines, possibly due to their stronger electrostatic 
interaction with negatively charged bacterial membranes.7 For instance, a series of bis-cyclic 
guanidine compounds were recently obtained from combinatorial libraries and showed broad-
spectrum antibacterial activity, however, their structures lack symmetry and rational design, and thus 
could face challenge in further optimization.25 Building upon these studies, we anticipated that bis-
guanidine compounds bearing amphipathic structures could mimic mechanism of action of HDPs. 
Indeed, amphipathic xanthone derivatives bearing bis-arginine moieties recently demonstrated 
enhanced membrane selectivity, although they showed potent antimicrobial activity only against 
Gram-positive bacteria.26, 27 Brilacidin, a symmetric bis-guanidine investigational new drug candidate 
also designed to mimic the mechanism of action of HDPs, possesses an amphipathic structure to 
replicate the innate function of HDPs.28 As such, we envisioned that bis-cyclic guanidine compounds 
could be rationally designed to adopt cationic amphipathic structures, and thus capable of mimicking 
HDPs and revive as a promising approach to combat bacterial resistance.  
90 
 
5.2 Results and Discussion 
  Compared with HDPs which have large molecular weight (MW 1500‒3000 Da) and multiple 
cationic charges and hydrophobic groups, these small bis-cyclic guanidines could be facilely accessed 
and scaled-up without compromising antimicrobial activity and potential of combating drug 
resistance, thus they are envisioned to be more promising in antibiotic therapeutic development. We 
hypothesized that if bis-cyclic guanidine compounds are endowed with the ability of bacterial 
membrane action by incorporating hydrophobic residues, their overall structures would be 
amphipathic with positive charges. Therefore, they could interact with bacterial membrane effectively.  
As shown above, the amphipathic bis-cyclic guanidine compounds could be conveniently designed by 
using a linker to dimerize the five-membered cyclic guanidine moiety bearing different lipophilicities. 
The molecules were synthesized in a straightforward manner (Figure 5.5), allowing future 
optimization and development of this class of compounds at ease. To this end, a new series of bis-
cyclic guanidine compounds (MW 600‒900 Da) were synthesized (Figure 5.1), and tested against a 
panel of multidrug resistant bacteria (Table 5.1).16  As expected, some compounds showed exceptional 
in vitro and in vivo activity. When R1 was kept as the phenyl group and R2 was just proton (no 
substituent), no activity was detected for 1 and 2 with aliphatic (C4H8) or aromatic (m-phenylene) 
linker under the tested condition. We reasoned that compounds without hydrophobic group on cyclic 
guanidine do not lead to strong hydrophobic interaction with bacteria membranes, even although they 
could reach on the surface of negatively charged bacteria through electrostatic interactions. We thus 
hypothesized that appending hydrophobic groups onto the cyclic guanidine ring would enhance the 
interaction of the compounds to associate with bacterial membranes.  
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Figure 5.1 The structures of compounds 1‒9. 
  As anticipated, bearing an ethyl group on the cyclic guanidine ring, compounds 3 and 4 started 
to show excellent activity against Gram-negative bacteria E. coli with MICs of 1.5 and 3 μg/mL, 
respectively.  
  Replacement of ethyl group in 3 and 4 with the 3-phenylpropyl group led to compounds 5 and 
6, respectively. Intriguingly, with more hydrophobic and longer chains which were expected to better 
span the phospholipid bilayer, both 5 and 6 displayed exciting antibacterial activity with MICs less 
than 3.0 μg/mL for Gram-negative bacteria (except for P. aeruginosa), and less than 3.0 μg/mL against 
Gram-positive bacteria. It is particularly noted that the MIC of compound 5 was as potent as 0.33 
μg/mL, which is better or at least comparable to any known bis-cyclic guanidine compounds. It also 
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seemed p-phenylene and m-phenylene spacers do not impact activity intensively, as 3 and 4, and 5 and 
6 exhibited similar activity.  
Table 5.1 The antibacterial activity of compounds 1‒9. 
 
Cpd 
MIC (µg/mL) 
HC50 
(µg/mL) 
AI[b] Gram Positive Gram Negative 
MRSA MRSE VRE E. Coli PA KP 
1 >25 ND[a] ND >25 ND ND ND ND 
2 >25 ND ND >25 ND ND ND ND 
3 12 >25 >25 1.5 >25 >25 ND ND 
4 12 >25 >25 3.0 >25 >25 ND ND 
5 0.33 0.75 0.75 1.5 12 3.0 140 424 
6 3.0 1.5 1.5 3.0 25 3.0 >250 >83 
7 0.33 0.75 0.75 1.5 6.0 1.5 >250 >769 
8 0.16 0.75 0.75 0.75 4.0 0.75 >250 >1534 
9 >25 ND ND 3.0 ND ND ND ND 
D[c] 0.5 0.5 1.0 >25 >25 >25   
C[d] >25 >25 >25 0.5 1.0 0.5   
[a]ND, Not determined because compounds are not active. [b]AI, Activity Index, determined by 
HC50/MICMRSA. 
[c]D, Daptomycin, is included for comparison against gram-(+) bacteria. [d]C, Colistin, 
was included in the test as the positive control against gram-(‒) bacteria. 
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  The subsequent studies revealed that the aliphatic chain C6H13 as the R2 group (Table 1) could 
further enhance the antimicrobial activity. Both 7 and 8 exhibited potent and broad-spectrum activity 
against all tested bacterial strains. It was very encouraging that compound 8 had remarkable MICs of 
0.75 μg/mL toward most strains, and MIC of 0.16 μg/mL against MRSA. In addition, both compound 
7 and 8 were very selective, as their hemolytic activity are all more than 250 μg/mL, which 
demonstrated 769 and 1534 folds of selectivity against MIC values of MRSA, respectively. It is known 
that daptomycin29 and colistin30 are last-resort antibiotics and active against Gram-positive and Gram-
negative bacteria, respectively. Compound 8 had almost same or even better activity against Gram-
positive bacteria compared with daptomycin, meanwhile showed comparable activity against Gram-
negative bacteria compared with colistin, suggesting its promising therapeutic potential. Further 
attempts using more hydrophobic 2-adamantylethyl  (compound 9) as the R2 group did not yield 
compounds with more potent and broad-spectrum activity. 
 
Figure 5.2 Fluorescence micrographs of MRSA and E. coli that were treated or not treated with 10 
µg/mL of 8 for 2 h. a1, control, no treatment, DAPI stained; a2, control, no treatment, PI stained. a3, 
treatment with 8, DAPI stained; a4, treatment with 8, PI stained. Scale bar = 10 µm. 
To test the hypothesis that our compounds could possess the mechanism of action of HDPs 
and interact with bacterial membranes, fluorescence microscopic studies were conducted to evaluate 
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the ability of most potent compound 8 to compromise membranes of E. coli (Gram-negative 
bacterium) and S. aureus (Gram-positive bacterium). As well known, 4',6-diamidino-2-phenylindole 
(DAPI) could stain membranes of bacterial cells with blue fluorescence regardless of cell viability, 
whereas the red fluorescence of propidium iodide (PI) due to the DNA intercalation could only be 
observed in the presence of impaired membranes. As shown in Fig. 5.2, treatment of 8 gave rise to the 
red fluorescence under the PI channel in both S. aureus and E. coli groups, indicating that the 
membranes of these bacteria were disrupted. Moreover, significant aggregation of S. aureus occurred 
in the presence of 8, probably due to the loss of membrane potential upon membrane leakage.18  
  We next conducted time-kill studies to investigate the bacterial killing kinetics of compounds 
7 and 8 by using E. Coli. As shown in Figure 5.3a and 5.3b, both compounds could kill E. Coli very 
rapidly. Cell colonies were counted in agar plates at 12.5, 25, and 50 μg/mL. Compound 7 at the 
concentration of 12.5 or 25 μg/mL could completely remove all bacterial in 2 h, and at 50 μg/mL it 
could remove bacterial clearly in just 0.5 h (Fig. 3a). Notably, Compound 8 could rapidly kill E. Coli 
completely in 0.5 h even at the concentration of 12.5 μg/mL (Fig. 5.3b). These data supported that 7 
and 8 could kill bacteria in a similar way to that of HDPs.  
  One of the biggest concerns of current antibiotics is the bacterial resistance as described vide 
supra, while HDPs take advantage of no immediate drug resistance in bacteria due to lack of defined 
molecular targets as they disintegrate bacterial membranes. To assess the potential emergence of 
bacterial resistance toward these cyclic guanidines, the compound 8 was employed for further 
investigation. The compound was incubated with either MRSA or E. Coli in the well at the 
concentration of half-MIC every day and tested for their activity through 14 successive passages. As 
shown in Fig. 5.3c, MICs of 8 were virtually constant after 14 passages, indicating that they do not 
readily induce drug resistance in both MRSA and E. Coli. These outcomes suggest that our bicyclic 
95 
 
guanidine compounds are not vulnerable in developing drug resistance, which is analogous to the 
mechanism of action of HDPs.  
  The bacterial biofilm is another severe problem because bacteria in biofilm generally tolerate 
antibiotic treatment and thus more difficult to eradicate than planktonic cells.31, 32 Moreover, the 
bacterial biofilm infection could contaminate medical devices,33 therefore, organ catheters and 
implants coated with biofilm-inhibiting antibacterial agents are needed as effective therapeutic 
methods.34 Biofilms formed by MRSA and E. coli have frustrated the treatment of persistent bacterial 
infections.35, 36 We thus sought to evaluate the compound 8 for its ability to inhibit biofilm formation 
of MRSA and E. coli. As shown in Fig. 5.3d, at 0.19 μg/mL, 8 could inhibit 85% of biofilm formation 
of MRSA and 38% of biofilm formation of E. coli. At the concentration of 0.39 μg/mL, 8 could 
completely eradicate biofilm formation of MRSA and almost 90% of biofilm formation of E. coli. 
This analysis revealed that the bis-cyclic guanidine compound is an efficient biofilm formation 
inhibitor.  
 
Figure 5.3 Time-kill curves of 7 (a) and 8 (b) for E. Coli. The killing activity was monitored for the 
first 2 h. (c) Drug-resistance study of 8 toward MRSA and E. Coli. (d) Biological activity of 8 on 
inhibition of biofilm by E. Coli.  
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  The development of membrane-active antibacterial peptides for treatment of bacterial 
infections has been suffered from difficulties with systematic toxicity and tissue distribution, thus few 
compounds have been reported with in vivo activity and advanced into clinical trials.37-39  We 
envisioned that as small molecules, our bis-cyclic guanidines may possess better therapeutic potential. 
The thigh burden model is a widely used animal model for evaluating preclinical antimicrobial activity 
of compounds.17, 40 We thus employed the thigh burden model to evaluate the in vivo anti-infective 
activity of compounds 7 and 8, in which the thigh muscle of neutropenic mice was inoculated with S. 
aureus, followed by intravenous (i.v.) administration of corresponding compounds. As shown in Fig. 
5.4, significant activity was observed for both compounds at dose of 5 mg/kg when administered twice 
with a 6-hour interval between injections. A 3-log10 decrease in colony-forming unit (CFU) was 
observed for compound 7, while more significant decrease (5-log10 CFU) was observed for compound 
8, indicating that compound 8 has better efficacy. The result suggested that our compounds provided 
significant protection against infection with S. aureus. 
 
Figure 5. 4 In vivo efficacy of the compounds 7 and 8 in thigh-infection mouse model. Neutropenic 
mice (n = 4 per group) were inoculated in the posterior thigh muscles with S. aureus ATCC 33591 at 
1 × 106 CFU per thigh and then treated with 7 and 8 (5 mg/kg per dose) by i.v. bolus injection in the 
tail vein at 1 and 7 h after infection. 
97 
 
5.3 Conclusions 
  In summary, we have developed a new class of bis-cyclic guanidine-based small molecules 
(MW 600‒900 Da) starting from simply α-Phenylalanine. These molecules exhibit remarkable 
potency against a panel of multidrug-resistant Gram-positive and Gram-negative bacteria. Although 
other antimicrobial mechanisms cannot be excluded, our studies suggest that these compounds could 
kill bacteria rapidly by disrupting bacterial membranes, a mechanism analogous to that of HDPs. The 
hypothesis is further supported by the fact that the susceptibility of MRSA bacteria to the lead 
compounds remained nearly unchanged even after 14 passages. Furthermore, antibiotic therapeutic 
potential of these molecules was confirmed in the MRSA-infected thigh burden mouse model. Our 
work illustrated the potential of bis-cyclic guanidines for the development of potent antimicrobial 
molecules with molecular masses in the range of 600‒900. Further studies on optimization of activity 
and selectivity, as well pharmacokinetic assessments are underway in our lab. 
5.4 Experimental Section 
General information. α-Phenylalanine was purchased from Chem-Impex International, Inc. Solvents 
and other reagents were purchased from either Sigma-Aldrich or Fisher Scientific and were used 
without further purification. The final products were purified on a Waters Breeze 2 HPLC system, and 
lyophilized on a Labcono lyophilizer. The purity of the compounds was determined to be >95% by 
analytical HPLC (1 mL/min flow, 5% to 100% linear gradient of solvent B (0.1% TFA in acetonitrile) 
in A (0.1% TFA in water) over 50 min was used). NMR data of compound 7 were collected on a 
Varian Inova 600 instrument, and others were obtained on a Varian Inova 500 instrument. 
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Synthesis of desired compounds. 
 
Figure 5.5 The general synthetic scheme of cyclic guanidine dimers 
The typical procedure for the synthesis of 9 is shown below. The other compounds were 
synthesized according to the same procedure as compound 9. Different aldehydes were used at the 
first step to give different compounds with various side chains.  
 
Figure 5.6 Typical synthetic route for compound 9 
Synthesis of the intermediate build block C5. Compound C1 (TFA salt, 10.8g, 33.6 mmol) was 
dissolved in MeOH and treated with TFA (5.1 mL, 33.6 mmol) before adding to a solution of 2-
((3R,5R,7R)-adamantan-1-yl) acetaldehyde (6g, 33.6mmol) in MeOH and acetic acid (2 mL, 67.2 
mmol). After stirring for 10 min under ice/H2O bath, NaBH3CN (3.2g, 50.4 mmol) was added portion 
99 
 
wise. The reaction was stirred for 3 h at room temperature before solvent was removed. The crude 
mixture was treated with NaHCO3 (aq.) and extracted with EtOAc, and the organic layer was separated 
and evaporated to give an oil crude, which was purified by silica gel column chromatography to give 
8.2 g of the desired secondary amine. Boc2O (7g, 32.4 mmol) was added in the THF/H2O (1:1, v/v) 
solution of this intermediate containing NaHCO3 (3.6g, 43.2 mmol) and allowed to react for 5 h, after 
which EtOAc was added and the organic layer was collected. The solvent was removed in reduced 
pressure to give the colorless crude, which was purified by flash column chromatography to give 8.5 
g of compound C2. Next, compounds C2 was taken in THF and reduced by LiAlH4 (687 mg, 18 mol) 
for 30 min at -20 oC, then water was added to quench the reaction. The mixture was extracted with 
EtOAc, and the organic layer was separated and the solvent was removed in vacuo to give the crude 
C3, which was used in the next reaction without any further purification. Compound C3 was converted 
into compound C4 with the same procedure for the synthesis of compound C2. BOC protecting group 
was attached as the same procedure for attaching BOC onto compound C2, followed by hydrogenation 
to remove benzyl protecting group in MeOH to give the building block C5 as a white solid after 
filtration and concentration. 
Synthesis of compound 9. Building block C5 (300 mg, 0.52 mmol), HOBt (159 mg, 1.04 mmol), 
DIPEA (129 μL, 1.04 mmol), and m-Phenylenediamine (34 mg, 0.32 mmol) was dissolved in DMF (2 
mL) and then DCC (214 mg, 1.04 mmol) was added. The reaction mixture was stirred at room 
temperature for 24 h. The afforded byproduct DCU was filtered off and the filtration was added into 
water and extracted with EtOAc (×3). The organic phase was combined and washed with 1M HCl 
(×2), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The crude oil 
compound was treated with TFA in DCM (1:1, v/v) for 2 h to completely remove BOC protecting 
groups to yield crude compound C6. Subsequently, C6 was dissolved in acetonitrile (3 mL), to which 
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CNBr (4 eq.) was added carefully (caution: very toxic). The reaction was stirred for 12 h at room 
temperature. 1M NaOH solution was added carefully, followed by proper amount of bleach to 
deactivate excessive CNBr. The mixture was filtered through a millpore filter and purified by HPLC 
purification on Waters HPLC system, and the desired fraction was lyophilized to give the pure product 
9. 
Compound 1. 1H NMR (500 MHz, CD3OD) δ 7.31‒7.34 (m, 4H), 7.22‒7.26 (m, 6H), 4.22‒4.28 (m, 
2H), 3.94, 3.98 (ABq, JAB = 12.0 Hz, 4H), 3.72 (t, J = 9.5 Hz, 2H), 3.42 (dd, J = 9.0, 6.0 Hz, 2H), 3.22 
(t, J = 5.5 Hz, 4H), 2.93 (ddd, J = 15.5, 14.0, 7.0 Hz, 4H), 1.54 (dtt, J = 9.0, 6.0, 3.5 Hz, 4H). 13C 
NMR (125 MHz, CD3OD) δ 167.0, 159.2, 136.1, 128.9 (2C), 128.4 (2C), 126.7, 54.5, 53.2, 46.2, 40.2, 
38.7, 26.2. HRMS (ESI) C28H39N8O2 [M+H]
+ calcd = 519.3190; found = 519.3193. 
Compound 2. 1H NMR (500 MHz, CD3OD) δ 8.05 (s, 1H), 7.31‒7.34 (m, 4H), 7.22‒7.27 (m, 9H), 
4.25‒4.30 (m, 2H), 4.14, 4.19 (ABq, JAB = 18.0 Hz, 4H), 3.79 (t, J = 9.0 Hz, 2H), 3.50 (dd, J = 9.5, 
5.5 Hz, 2H), 2.93 (ddd, J = 15.0, 13.5, 6.5 Hz, 4H), 1.54 (dtt, J = 9.0, 6.0, 3.5 Hz, 4H). 13C NMR (125 
MHz, CD3OD) δ 165.2, 159.3, 138.5, 136.1, 128.9 (2C), 128.4 (2C), 126.7, 115.4, 111.2, 54.6, 53.3, 
46.5, 40.3. HRMS (ESI) C30H35N8O2 [M+H]
+ calcd = 539.2877; found = 539.2877. 
Compound 3. 1H NMR (500 MHz, CD3OD) δ 7.52 (brs, 4H), 7.31‒7.33 (m, 4H), 7.22‒7.28 (m, 6H), 
4.29‒4.34 (m, 2H), 4.14, 4.10 (ABq, J = 18.0 Hz, 4H), 3.65 (t, J = 11.5 Hz, 2H), 3.53‒3.61 (m, 2H), 
3.38‒3.45 (m, 4H), 3.21 (dd, J = 13.5, 4.5 Hz, 2H), 2.86 (dd, J = 13.5, 8.5 Hz, 2H), 1.26 (t, J = 7.5 
Hz, 6H). 13C NMR (125 MHz, CD3OD) δ 165.1, 157.9, 135.7, 134.3, 128.9 (2C), 128.5 (2C), 126.8, 
120.1 (2C), 57.8, 51.8, 37.8, 37.5, 11.2. HRMS (ESI) C34H43N8O2 [M+H]
+ calcd = 595.3503; found = 
595.3488. 
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Compound 4. 1H NMR (500 MHz, CD3OD) δ 8.05 (d, J = 1.5 Hz, 1H), 7.31‒7.34 (m, 4H), 7.23‒7.28 
(m, 9H), 4.28‒4.34 (m, 2H), 4.15, 4.11 (ABq, J = 17.5 Hz, 4H), 3.63 (t, J = 9.5 Hz, 2H), 3.56 (quintet, 
J = 6.5 Hz, 2H), 3.36‒3.44 (m, 4H), 3.21 (dd, J = 13.5, 4.5 Hz, 2H), 2.85 (dd, J = 13.5, 9.0 Hz, 2H), 
1.26 (t, J = 7.0 Hz, 6H). 13C NMR (125 MHz, CD3OD) δ 165.2, 157.9, 138.5, 135.7, 129.0 (2C), 128.4 
(2C), 126.8, 115.4, 111.2, 57.8, 51.7, 37.8, 37.6, 11.2. HRMS (ESI) C34H43N8O2 [M+H]
+ calcd = 
595.3503; found = 595.3490. 
Compound 5. 1H NMR (500 MHz, CD3OD) δ 7.53 (s, 4H), 7.17‒7.32 (m, 20H), 4.22‒4.27 (m, 2H), 
4.0 (s, 4H), 3.60 (t, J = 9.5 Hz, 2H), 3.50‒3.57 (m, 2H), 3.40 (dd, J = 9.5, 5.0 Hz, 2H), 3.33 (dd, J = 
8.5, 5.5 Hz, 2H), 3.08 (dd, J = 13.5, 5.0 Hz, 2H), 2.83 (dd, J = 13.5, 8.0 Hz, 2H), 2.61‒2.73 (m, 4H), 
1.91‒2.05 (m, 4H). 13C NMR (125 MHz, CD3OD) δ 165.0, 158.0, 140.9, 135.7, 134.3, 128.9 (2C), 
128.4 (2C), 128.2 (2C), 128.0 (2C), 126.8, 125.8, 120.0, 58.0, 51.6, 42.4, 37.4, 32.1 (2C), 28.3. HRMS 
(ESI) C48H55N8O2 [M+H]
+ calcd = 775.4442; found = 775.4443. 
Compound 6. 1H NMR (500 MHz, CD3OD) δ 8.05‒8.12 (m, 1H), 7.17‒7.32 (m, 23H), 4.19‒4.25 (m, 
2H), 4.12, 4.09 ((ABq, JAB = 18.0 Hz, 4H), 3.60 (t, J = 8.5 Hz, 2H), 3.52 (quintet, J = 7.5 Hz, 2H), 
3.39 (dd, J = 9.5, 5.0 Hz, 2H), 3.27‒3.33 (m, overlapped with CD3OD, 2H), 3.07 (dt, J = 13.5 Hz, 5.4 
Hz, 2H), 2.82 (ddd, J = 13.0, 9.0, 3.0 Hz, 2H), 2.60‒2.72 (m, 4H), 1.92‒2.02 (m, 4H). 13C NMR (125 
MHz, CD3OD) δ 165.2, 158.0, 140.8, 138.5, 135.6, 129.0 (2C), 128.4 (2C), 128.2 (2C), 128.0 (2C), 
126.8, 125.8, 115.3, 58.0, 51.6, 42.3, 37.4, 32.1 (2C), 28.3. HRMS (ESI) C48H55N8O2 [M+H]
+ calcd 
= 775.4442; found = 775.4438. 
Compound 7. 1H NMR (600 MHz, CD3OD) δ 7.50 (brs, 4H), 7.29‒7.32 (m, 4H), 7.22‒7.26 (m, 6H), 
4.26‒4.31 (m, 2H), 4.08 (s, 4H), 3.65 (t, J = 9.6 Hz, 2H), 3.45 (ddd, J = 15.0, 9.0, 6.6 Hz, 2H), 3.40 
(dd, J = 9.6, 5.4 Hz, 2H), 3.24‒3.27 (m, 2H), 3.14 (dd, J = 13.8, 4.8 Hz, 2H), 2.87 (dd, J = 13.2, 8.4 
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Hz, 2H), 1.58‒1.69 (m, 4H), 1.32‒1.37 (m, 16H), 0.91 (t, J = 7.2 Hz, 6H). 13C NMR (150 MHz, 
CD3OD) δ 165.0, 158.0, 135.8, 134.3, 129.0 (2C), 128.4 (2C), 126.7, 120.0 (2C), 57.9, 51.7, 42.8, 
37.5, 31.1, 26.6, 25.8, 22.1, 12.9. HRMS (ESI) C42H59N8O2 [M+H]
+ calcd = 707.4755; found = 
707.4748. 
Compound 8. 1H NMR (500 MHz, CD3OD) δ 8.05 (s, 1H), 7.31‒7.34 (m, 4H), 7.24‒7.28 (m, 9H), 
4.27‒4.32 (m, 2H), 4.14, 4.10 (ABq, J = 18.0 Hz, 4H), 3.65 (t, J = 8.0 Hz, 2H), 3.47 (ddd, J = 15.0, 
9.0, 6.5 Hz, 2H), 3.42 (dd, J = 9.5, 5.5 Hz, 2H), 3.24‒3.27 (m, 2H), 3.16 (dd, J = 13.5, 5.0 Hz, 2H), 
2.89 (dd, J = 13.5, 8.0 Hz, 2H), 1.59‒1.69 (m, 4H), 1.32‒1.37 (m, 12H), 0.92 (t, J = 7.0 Hz, 6H). 13C 
NMR (125 MHz, CD3OD) δ 165.2, 158.0, 138.5, 135.8, 129.0 (2C), 128.5 (2C), 126.8, 115.3, 111.1, 
62.9, 58.0, 42.9, 37.5, 31.1, 26.6, 25.8, 22.1, 12.9. HRMS (ESI) C42H59N8O2 [M+H]
+ calcd = 
707.4755; found = 707.4751. 
Compound 9. 1H NMR (500 MHz, CD3OD) δ 8.12 (t, J = 1.5 Hz, 1H), 7.34 (t, J = 7.5 Hz, 4H), 7.22‒
7.29 (m, 9H), 4.28‒4.33 (m, 2H), 4.15, 4.12 (ABq, J = 18.5 Hz, 4H), 3.70 (t, J = 9.5 Hz, 2H), 3.53 
(qd, J = 7.0, 5.5 Hz, 2H), 3.42 (dd, J = 10.0, 5.5 Hz, 2H), 3.16‒3.19 (m, 2H), 3.12 (dd, J = 14.0, 5.5 
Hz, 2H), 2.90 (dd, J = 14.0, 7.5 Hz, 2H), 1.95 (brs, 6H), 1.67‒1.77 (m, 12H), 1.52‒1.54 (m, 12H), 
1.44 (td, J = 13.0, 4.5 Hz, 2H), 1.35 (td, J = 12.0, 5.5 Hz, 2H). 13C NMR (125 MHz, CD3OD) δ 165.2, 
158.0, 138.6, 136.0, 129.0 (2C), 128.5 (3C), 126.8, 115.3, 111.2, 57.4, 51.9, 41.7 (3C), 39.6, 38.1, 
38.0, 36.6 (2C), 31.3, 28.6 (3C), 28.6. HRMS (ESI) C54H71N8O2 [M+H]+ calcd = 863.5694; found 
= 863.5670. 
Compound C5. 1H NMR (500 MHz, CD3OD) δ 7.25‒7.29 (m, 2H), 7.19‒7.21 (m, 3H), 3.73‒3.97 
(m, 3H), 3.59 (s, 1H), 3.43‒3.50 (m, 1H), 2.95‒3.11 (m, 2H), 2.77‒2.81 (m, 2H), 1.88 (brd, 4H), 1.71 
(brd, 4H), 1.60 (brd, 4H), 1.28‒1.52 (m, 21H), 0.87‒0.92 (m, 3H). 13C NMR (125 MHz, CD3OD) δ 
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171.7, 155.8, 155.7, 128.9 (2C), 128.0 (2C), 126.0, 80.5, 80.3, 79.5, 79.2, 49.3, 42.0 (3C), 41.8, 36.8 
(3C), 36.5, 31.2, 28.6 (4C), 28.5, 27.6, 27.5 (2C), 27.4, 27.3, 27.2. HRMS (ESI) C33H51N2O6 [M+H]
+ 
calcd = 571.3742; found = 571.3763. 
Minimum inhibitory concentrations (MICs) against bacteria. We text the antimicrobial activity of 
the 8 compounds on six bacteria strains: MRSA (ATCC 33591), MRSE (RP62A), KP (ATCC 13383), 
PA (ATCC27853), E. coli (ATCC 25922), VER (ATCC 700802) according to the same procedures 
reported previously.1 Two-fold serial dilutions of compounds (0.1‒25 µg/mL) were used in the assay. 
The experiments were repeated at least three times with duplicates each time. The absorption at 600 
nm wavelength was read on a Biotek Synergy HT microtiter plate reader. 
Hemolytic assays. The freshly drawn rat red blood cells (hRBCs) were washed with 1× PBS buffer, 
and centrifuged at 3500 rpm for 10 min. The rest procedures were followed as reported previously.1 
The experiment was repeated at least three times with duplicates each time.The hemolysis activity was 
calculated by the formula % hemolysis = (Abssample-AbsPBS)/(AbsTriton-AbsPBS) ×100%.  
Fluorescence microscopy. 2 The PF assay was used to assess the ability of the compound 8 to 
compromise bacterial membranes. The compound 8 was incubated with the bacteria at 37 °C for 2 h 
after MRSA and E. Coli grew to mid-logarithmic phase. After centrifuged at 5000 rpm for 15 min, the 
cell pellets were washed with the PBS buffer for three times, and incubated with DAPI (10 µg/mL) or 
PI (5 µg/mL) for 15 min sequentially on ice in the dark. The mixture was then centrifuged and the 
pellets were washed with the PBS buffer. Next, 10 µL of the samples were placed on chamber slides 
and observed under Zeiss Axio Image Zloptical microscope using 100× oil-immersion objective. 
Time kill study. The kinetics of bacteria killing by the lead compounds 7 and 8 were also tested. The 
bacteria E. Coli were grown to mid-logarithmic phase in TSB medium to make the suspension of 106 
CFU/ml. The suspension was incubated with different concentrations of 7 or 8 (12.5 μg/mL, 25 μg/mL, 
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and 50 μg/mL) for 10 min, 30 min, 1 h and 2 h respectively. The mixtures were diluted by 102 to 104 
fold and spread on TSB agar plates. After incubation at 37 °C 12 h, the colonies on the plates were 
counted and plotted against the incubation time. 
Drug resistance study. 3 Bacteria in wells containing concentration of 1/2 MIC of the compounds 7 
and 8 were used to make bacterial suspension (106 CFU/ml) for the next measurement of MICs. The 
experiment was repeated each day for 14 passages. 
Inhibition of biofilms. 4 Overnight grown bacteria MRSA and E. Coil were inoculated into fresh 10% 
of MHII broth at a ratio of 1:100. Afterwards, 100 µL of inoculated culture was incubated with 
appropriated amounts of compounds 7 and 8 in 96-well plate, which was then incubated at 37 °C for 
overnight. Optical density of each wells was recorded (wavelength 600 nm) and then the biofilm 
biomass were recorded by the crystal violet (CV) method. Relative biofilm biomass values were 
normalized by the biomass value of control (no compound added). Data were presented in mean value 
of three replicates. 
In vivo study of mouse thigh burden infection model. All protocols and methods associated with 
animal experiments were approved by University of South Florida (USF) Institutional Animal Care 
and Use Committee. The in vivo experiment on the mouse model of the thigh burden infection with 
MRSA was conducted adapted from previously reported protocol.5 The CD-1 female mice which were 
6 to 8 weeks old and around 25 g in weights were used for the study. Neutropenic Mice were induced 
by injecting cyclophosphamide (150 mg/kg) intraperitoneally twice at 4 and 1 days before bacterial 
inoculation. One MRSA colony from trypic soy agar (TSA) cultures was allowed to grow in trypic 
soy broth (TSB) overnight at 37 °C, then 100 μL culture was withdrawn and diluted with TSB to a 
total volume of 4 mL, which was subsequently incubated at 37 °C for another 6 h. The bacterial culture 
was then diluted in sterile PBS to give the final inoculum concentration of approximate 106 CFU/mL. 
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The thigh burden infection model was established by injecting both posterior thighs of mice with 100 
μL of inoculums. Two doses of the compounds 7 and 8 were given at 1 h and 7 h by i.v. bolus injection 
in the tail vein at 5 mg/kg per dose of drugs after bacterial infection. Thighs were harvested at 25 h for 
both groups after bacterial inoculation. Thigh muscles were collected in a sterile tared tube, to which 
5 mL sterile PBS was added. The mixture was then homogenized with a tissue homogenizer (BioSpec 
product tissue tearor 985-370) for approximately 30 sec. 100 mL of serial diluted aliquots were plated 
on trypic soy agar plates, which were incubated for 24 h at 37 °C. The formed colonies were counted 
to calculate CFU per thigh.  
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CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS 
In this chapter of the dissertation, we are summarizing the results of our projects and providing 
an idea for the future direction of our projects in a real-world application. In our projects we have 
explored the antibacterial activity of polymers, dendrimers and small molecules for their potency, 
selectivity against a wide range of bacteria. 
We have developed a biodegradable polycarbonate by ring opening polymerization technique, 
which are highly selective and potent against Gram-positive bacteria. These biodegradable molecules 
can be suitable for in vivo applications. Here we have reported the polymers that can act against a 
particular strain of bacteria i.e, Gram-positive strain. Further design of polymers can be made by 
varying the cationic and hydrophobic groups of the polymers, which might result in activity against a 
broad spectrum of bacteria. By synthesizing the amino acid derived cationic monomers, the cationic 
nature of the polymer can be potentially enhanced. The activity may be further enhanced by increasing 
the number of equivalents of the hydrophilic and the hydrophobic monomers used in the polymer 
synthesis. Apart from targeting the polymers for antibacterial application, they can also be designed 
for their significant application in targeted drug delivery, anti-coating agents and antifungal agents. 
Moving forward, we have synthesized the dendrimers that can act as broad spectrum antibacterial 
agents. The unimicellar nature of the dendrimers has increased the potential of the molecule to act 
against a wide range of bacteria. However, the selectivity was comparatively poor than the polymers. 
Future direction can be laid on designing the groups on the dendrimers in a way that they can potential 
increase the selectivity and can retain or improve the potency. Due to the presence of the internal voids 
in the dendrimer, they can also be used as drug delivery agents. The end groups of the dendrimers can 
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be modified with a ligand and can be tested for various biomedical applications. As dendrimers have 
found to be highly toxic, the antibacterial activity can also be increased by potential binding of the 
dendrimers to currently available antibiotics that are in the market. This binding of the dendrimers 
with the antibiotics may increase the activity by synergistic effect.  
Lastly, our research studies have focused on using these polymers and dendrimers as drug 
delivery agents of the hydrophobic drugs for the treatment of colon cancer. The hydrophobic drugs 
miRNA lacks activity in the body due to short circulation time. Furthermore, miRNA is rapidly 
degraded and gets aggregated in the presence of serum proteins. In order to deliver miRNA  to the 
target site for the treatment of the colon cancer PEG-amphiphilic cationic polymeric micelles were 
used for the encapsulation of the miRNA. The results showed that the polymers were able to 
successfully encapsulate the miRNA. The preliminary in vivo data on the mice proved that the miRNA 
encapsulated polymeric micelles has considerably reduced the hepatoma in the mice. These polymeric 
micelles were observed to be in the size range of 100-200nm which makes them compatible to pass 
through the blood brain barrier. The factors that further effect the in vivo efficacy of the polymeric 
nanoparticles is currently underway. The limitation of this study is the polymeric micelles are not 
target specific and show the activity in the body by passive delivery of the drug in the body. The 
limitation has further led us to design the nanoparticles that can release the cargo at the targeted 
location. For this study, we have synthesized a cationic amphiphilic monomer that can bind to the 
anticancer tanshinone drug and release the drug when there is a change in the pH inside the body.  A 
floroscent tag was attached to the polymer by covalent binding to keep track of the delivery of the 
cargo by polymer nanoparticles while conducting the in vivo studies. At this time of writing, we don’t 
have the complete in vivo data of the polymers that were being used as drug delivery agents. However, 
we would expect these polymer nanoparticles to be developed as potential drug delivery agents.
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APPENDIX A1: 1H NMR of Polymers P1-P8 and Monomer 1 
Figure S1. 1H NMR (400 MHz, CDCl3) of Monomer 1. 
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Figure S2. 1H NMR (400 MHz, CDCl3) of P1. 
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Figure S3. 1H NMR (400 MHz, CDCl3) of P2. 
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Figure S4. 1H NMR (400 MHz, CDCl3) of P3. 
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Figure S5. 1H NMR (400 MHz, CDCl3) of P4. 
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Figure S6. 1H NMR (400 MHz, CDCl3) of P5. 
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Figure S7. 1H NMR (400 MHz, CDCl3) of P6. 
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Figure S8. 1H NMR (400 MHz, CDCl3) of P7. 
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Figure S9. 1H NMR (400 MHz, CDCl3) of P8. 
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APPENDIX A2. 1HNMR spectra of compounds 1–16 and γ-BB-2 
 
 
Compound 1 
 
Compound 2 
 
121 
 
 
 
 
Compound 3 
 
Compound 4 
 
122 
 
 
 
 
Compound 5 
 
Compound 6 
 
123 
 
 
 
 
Compound 7 
 
Compound 8 
 
124 
 
 
 
 
Compound 9 
 
Compound 10 
 
125 
 
 
 
Compound 11 
 
Compound 12 
 
126 
 
 
 
Compound 13 
 
Compound 14 
 
127 
 
 
 
 
Compound 15 
 
Compound 16 
 
128 
 
 
HPLC analysis of compounds 1 ̶ 16 
Table S1. HPLC purities and retention time of compounds 1 ̶ 16 
Compound Name Purity (based on analytical HPLC) (%) Retention Time (min) 
1 99.50 17.23 
2 98.21 18.63 
3 100 18.12 
4 97.23 16.37 
5 99.51 20.42 
6 98.78 20.73 
7 99.78 22.77 
8 98.62 31.44 
9 99.54 24.04 
10 99.20 24.50 
11 96.54 26.75 
12 98.13 26.85 
γ-BB-2 
129 
 
13 99.75 25.05 
14 98.22 22.23 
15 98.11 23.18 
16 99.81 22.63 
 
HPLC spectra of compounds 1 ̶ 16 
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APPENDIX A3: 1H NMR (CD3OD) and 13C NMR (CD3OD) spectra of compounds 1–9, and C5 
 
 
Compound 1 
 
Compound 1 
 
134 
 
 
 
Compound 2 
 
Compound 2 
 
135 
 
 
 
Compound 3 
 
Compound 3 
 
136 
 
 
 
Compound 4 
 
Compound 4 
 
137 
 
 
 
 
Compound 5 
 
Compound 5 
 
138 
 
 
 
Compound 6 
 
Compound 6 
 
139 
 
 
 
 
Compound 7 
 
Compound 7 
 
140 
 
 
 
 
Compound 8 
 
Compound 8 
 
141 
 
 
 
Compound 9 
 
Compound 9 
 
142 
 
 
 
 
 
 
Compound C5 
 
Compound C5 
 
143 
 
HPLC analysis of compounds 1‒9 
Table S1. HPLC purities and retention time of compounds 1‒9 
Compound Name Purity (based on HPLC) (%) Retention Time (min) 
1 97.68 15.24 
2 96.88 17.32 
3 99.82 18.74 
4 98.82 19.51 
5 99.79 26.23 
6 99.81 26.33 
7 98.55 27.25 
8 96.31 27.15 
9 99.30 33.72 
 
HPLC spectra of compounds 1‒9 
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